
<!DOCTYPE html>
<html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#">
  
<!-- Mirrored from investors.scholarrock.com/node/9561/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:08:01 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=UTF-8" /><!-- /Added by HTTrack -->
<head>
    <title>SEC Filing - Scholar Rock, Inc.</title>
    <meta name="robots" content="noindex">
    <link rel="stylesheet" media="all" href="../../sites/g/files/knoqqb56236/files/css/css_-Ogun-b4Vwq8nD6qwBoEYuBhEF_0grnAaUrH4akFvLUcd37.css?delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl" />

    
    <!-- IrwinIQ Tag Manager --> <script> (function(w,d){ var _mtm = w._mtm = w._mtm || []; _mtm.push({'mtm.startTime': (new Date().getTime()), 'event': 'mtm.Start'}); var g=d.createElement('script'), s=d.getElementsByTagName('script')[0]; g.async=true; g.src='../../../analytics.imirwin.com/js/container_XFyWYf0m.js'; s.parentNode.insertBefore(g,s); })(window, document); </script> <!-- End IrwinIQ Tag Manager -->

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'../../../www.googletagmanager.com/gtm5445.html?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WTGMF33');</script>
<!-- End Google Tag Manager -->

<!-- Google Tag Manager (noscript) -->
<noscript><iframe src="../../../www.googletagmanager.com/nsca0c.html?id=GTM-WTGMF33"
height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
<!-- End Google Tag Manager (noscript) -->
  </head>
  <body class="body-sidebars-first nir-node nir-node--type-nir-sec-filing nir-node--9561 page-template-default page page-parent wp-custom-logo wp-embed-responsive full-width-content genesis-breadcrumbs-visible genesis-singular-image-hidden genesis-footer-widgets-visible top-parent-investors-media investors-media has-no-blocks elementor-default elementor-page cbp-spmenu-push cookies-set cookies-accepted body_classes" id="body" cz-shortcut-listen="true">
      <div class="region region-content">
    <div id="block-nir-pid2662-websitenoticeblock" class="block--website-notice-block block--website-notice-block--9561 block--content--website-notice-block block--content--website-notice-block--9561 block--24a64b1d-13aa-4b20-8029-2df59f99a96c block--24a64b1d-13aa-4b20-8029-2df59f99a96c--9561 block block-nir-website-notices block-website-notice-block">
  
    
      
  </div>
<div data-drupal-messages-fallback class="hidden"></div>

<div id="block-nir-pid2662-content" class="block--system-main-block block--system-main-block--9561 block--content--system-main-block block--content--system-main-block--9561 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0 block--c4d2f333-a7f8-46c4-afc3-3e36992b73c0--9561 block block-system block-system-main-block">
  
    
      <div class="nir-sec-header"><div class="logo"><img src="../../sites/g/files/knoqqb56236/files/Logo.png" alt="Scholar Rock, Inc." />
</div><div class="sec-docs">View:  <div class="field ixbrl-link">
    <a href="ixbrl-viewer"></a>
  </div>
  <div class="file-link">
  <span class="file file--mime-application-rtf file--general"> <a href="../../static-files/0001157523-23-001060.rtf%3b%20filename_%3dUTF-8%27%270001157523-23-001060.rtf" type="application/rtf" title="0001157523-23-001060.rtf">Download DOC</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-pdf file--application-pdf"> <a href="../../static-files/0001157523-23-001060.pdf%3b%20filename_%3dUTF-8%27%270001157523-23-001060.pdf" type="application/pdf" title="0001157523-23-001060.pdf">Download PDF</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-vnd-ms-excel file--x-office-spreadsheet"> <a href="../../static-files/0001157523-23-001060.xls%3b%20filename_%3dUTF-8%27%270001157523-23-001060.xls" type="application/vnd.ms-excel" title="0001157523-23-001060.xls">Download XLS</a></span><span class="filesize"> </span>
</div>
  <div class="file-link">
  <span class="file file--mime-application-octet-stream file--general"> <a href="../../sec-filings/sec-filing/8-k/0001157523-23-001060.html" type="application/octet-stream" title="0001157523-23-001060-ex-101-sch---xbrl-taxonomy-extension-schema.xsd">Download XBRL</a></span><span class="filesize"> </span>
</div>
</div></div>
    <XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:srrk="http://scholarrock.com/20230630" xmlns="../../../www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: business wire
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_519c1ffdba27485a88e3520e6cbdc84c" contextRef="c20230630to20230630" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_efe5e420d7154287a5b43e5435911680" contextRef="c20230630to20230630">0001727196</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="#srrk-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230630to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001727196</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div>
      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">UNITED






          STATES<br />
          SECURITIES AND EXCHANGE COMMISSION</span><br />
        <span style="font-weight: bold;">Washington, D.C. 20549</span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;">FORM






          <ix:nonNumeric name="dei:DocumentType" id="Fact_a2bff9fd151641b08a2397ad848f8171" contextRef="c20230630to20230630">8-K</ix:nonNumeric></span><br />
        _____________________</div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">CURRENT REPORT<br />
      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div>&#160;</div>

      <div style="text-align: center;">Date of Report (Date of earliest event Reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_545378a1d5db4000af095ecd69781cc4" contextRef="c20230630to20230630" format="ixt:date-monthname-day-year-en">June 30, 2023</ix:nonNumeric></div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_20043b85b052489084efeb2dce7220f1" contextRef="c20230630to20230630">Scholar Rock Holding Corp</ix:nonNumeric>oration</span><br />
        (Exact Name of Registrant as Specified in Charter)</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_3c23c553b0e343269d9ca6c0afb35b2a" contextRef="c20230630to20230630" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_672dcde8f2c24316ba355223951e9c55" contextRef="c20230630to20230630">001-38501</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_8d2a5ae9240e4b18b1699d0b825c46c1" contextRef="c20230630to20230630">82-3750435</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 34%; vertical-align: top;">
              <div style="text-align: center;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top;">
              <div style="text-align: center;">(I.R.S. Employer Identification Number)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: center;">
        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_1955abffa4954c429c3f3321f434696b" contextRef="c20230630to20230630">301 Binney Street</ix:nonNumeric><span style="font-weight: bold;">, </span><ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_3c4cc1089b3842c6ac14afcecf3b85a6" contextRef="c20230630to20230630">3rd Floor</ix:nonNumeric><span style="font-weight: bold;">, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_6a29dfd60d8849bb87c3da31854e35ff" contextRef="c20230630to20230630">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_8f0baa1518234ea0bce6e8eccead702e" contextRef="c20230630to20230630">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_16ef73194f6d466faab4641ca44076e0" contextRef="c20230630to20230630">02142</ix:nonNumeric></span></div>
<div>
        (Address of Principal Executive Offices) (Zip Code)</div>
</div>

      <div>&#160;</div>

      <div style="text-align: center;"><span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_28e70b0d6f4a4369993ada7991ea8803" contextRef="c20230630to20230630">857</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_63af3190978f448c971d3b199c0bde43" contextRef="c20230630to20230630">259-3860</ix:nonNumeric></span><br />
        (Registrant&#8217;s telephone number, including area code)</div>

      <div>&#160;</div>

      <div style="text-align: center;">(Former name or former address, if changed since last report)</div>

      <div>&#160;</div>

      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

      <div>&#160;</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_720556f4a8654196b1e357d0bff7c2e3" contextRef="c20230630to20230630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Written
        communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_0932ca5a60624a459a9944843302748e" contextRef="c20230630to20230630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Soliciting
        material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_97661906906f4bc0867ae27c240395ed" contextRef="c20230630to20230630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement







        communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

      <div style="text-indent: -18pt; margin-left: 36pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_5cbc0acd2a134e3ca778eccb281ce1a4" contextRef="c20230630to20230630" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160;<span class="BRFWTab" style="text-indent: 0px; font-size: 6pt;">&#160; </span>Pre-commencement







        communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

      <div>&#160;</div>

      <div>Securities registered pursuant to Section 12(b) of the Act:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Trading Symbol(s)</div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 39.56%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_e09256433bbb40f39fdd2f16ef85b9c0" contextRef="c20230630to20230630">Common Stock, par value $0.001 per share</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 22%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_22e988741e394d7c866b27b113f5adb6" contextRef="c20230630to20230630">SRRK</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 38%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_fa3f56c9b1ca4c8399b5d2d3d169671d" contextRef="c20230630to20230630" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div>&#160;</div>

      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2&#160;of the Securities Exchange Act of 1934 (17 CFR&#160;&#167;240.12b-2).&#160;Emerging growth company
        <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_9628a464141a444f9535eeeb13dc4fc6" contextRef="c20230630to20230630" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div>&#160;</div>

      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act.&#160; <ix:nonNumeric name="dei:EntityExTransitionPeriod" id="Fact_31ec45f7d4184e2dabc55b9db002640d" contextRef="c20230630to20230630" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div><br /></div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7.01. Regulation FD Disclosure.</div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On June 30, 2023, Scholar Rock Holding Corporation (the &#8220;Company&#8221;) issued a press release announcing 36-month topline results from its TOPAZ
        Phase 2 clinical trial for apitegromab for patients with nonambulatory spinal muscular atrophy (&#8220;SMA&#8221;). A copy of the press release is attached hereto as Exhibit 99.1.</div>

      <div><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">On June 30, 2023, Thomas O. Crawford, M.D., Professor of
          Neurology and Pediatrics at Johns Hopkins University and the lead principal investigator of the Company&#8217;s TOPAZ trial, presented at two podium presentations at the Cure SMA Research &amp; Clinical Care Meeting (&#8220;Cure SMA&#8221;) and presented new data
          from the Company&#8217;s Phase 2 TOPAZ trial extension period evaluating patient outcomes after 36 months of treatment with apitegromab. A copy of the podium presentations at Cure SMA may be accessed by visiting the Publications &amp; Posters section
          of the Company&#8217;s website at </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #0000FF;"><span style="text-decoration: underline;">https://scholarrock.com/our-science/publications-posters/</span></span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.</span></div>

      <div><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">On July 12, 2023, the Company will host a conference call and
          webcast at 9:00 am ET to discuss the 36-month data from the TOPAZ Phase 2 clinical trial and apitegromab&#8217;s potential to advance the standard of care in SMA. A copy of the presentation slides to be used by the Company during the conference call
          and webcast is attached hereto as Exhibit 99.2. A live webcast of the conference call may be accessed by visiting the Investors &amp; Media section of the Company&#8217;s website at </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">http://investors.scholarrock.com</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; color: #000000;">.</span></div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information in this report furnished pursuant to Item 7.01 and Exhibit 99.1 shall not be deemed &#8220;filed&#8221; for the purposes of Section 18
        of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as
        amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing. It may only be incorporated by reference in another filing under the
        Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 and Exhibit 99.1 of this report.</div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8.01. Other Events.</div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="text-decoration: underline;">TOPAZ Phase 2 Clinical Trial Update</span></div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On June 30, 2023, the Company announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36-months of
        treatment with apitegromab. These data showed that continued treatment with apitegromab over the extended treatment period was associated with substantial and sustained improvement in motor function, as well as improvements in patient-reported
        outcome measures in patients with nonambulatory Types 2 and 3 SMA receiving survival motor neuron (SMN)-targeted therapy.</div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nonambulatory patients (ages 2-21) experienced substantial and sustained gains in Hammersmith Functional Motor Scale-Expanded (HFMSE) and
        Revised Upper Limb Module (RULM) scores over the 36-month extended treatment period from baseline:</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35.57%; vertical-align: top; background-color: #A6A6A6; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">&#160;</td>

    <td style="width: 23.54%; vertical-align: top; background-color: #A6A6A6; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">12</span>-<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Month Data</span></div>
            </td>

    <td style="width: 20.44%; vertical-align: top; background-color: #A6A6A6; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">24-Month Data</div>
            </td>

    <td style="width: 20.44%; vertical-align: top; background-color: #A6A6A6; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">36-Month Data</div>
            </td>

  </tr>

  <tr>

    <td style="width: 35.57%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Mean Change from Baseline in HFMSE </span>(95%
                Confidence Interval)</div>
            </td>

    <td style="width: 23.54%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.6 points</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.2, 6.0)</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">N=32</div>
            </td>

    <td style="width: 20.44%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.2 points</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.9, 6.6)</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">N=29</div>
            </td>

    <td style="width: 20.44%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">4.0 points</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.0, 6.9)</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">N=28</div>
            </td>

  </tr>

  <tr>

    <td style="width: 35.57%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Mean Change from Baseline in</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">RULM </span>(95% Confidence
                Interval)</div>
            </td>

    <td style="width: 23.54%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1.3 points</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.2, 2.3)</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">N=31</div>
            </td>

    <td style="width: 20.44%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.3 points</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.2, 3.3)</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">N=31</div>
            </td>

    <td style="width: 20.44%; vertical-align: top; border-right: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2.4 points</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.1, 3.7)</div>
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">N=27</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the 36-month data, an observed case analysis was conducted, which pooled data for all nonambulatory patients (including those patients
        on 20 mg/kg of apitegromab for the full duration of the trial, and those who switched from 2 mg/kg to 20 mg/kg at various time intervals in year 2) and was based upon the available data. These analyses exclude data for patients post scoliosis
        surgery.</div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nonambulatory patients (ages 2-21) had improvements in PEDI-CAT (measure of activities of daily living) and PROMIS-Fatigue (a
        patient-reported outcome tool measuring fatigue) that were consistent and sustained at 36 months. The mean change in PEDI-CAT daily activity domain from baseline at 36 months was 2.2 (95% CI: &#8211;0.1, 4.5; N=17), indicating an improvement in the
        ability to perform daily activities. The mean change in PROMIS-Fatigue from baseline at 36 months was &#8211;4.6 (95% CI: &#8211;8.7, &#8211;0.5; N=14), indicating a decline in fatigue. These improvements in PEDI-CAT and PROMIS-Fatigue were generally consistent with
        improvements in motor function across the 36 months of the study period.</div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Treatment-emergent adverse events (TEAEs) at 36 months were consistent with previous reports at 12 and 24 months, with no new findings after
        an aggregate of 198 patient-years of exposure. TEAEs were mostly mild to moderate in severity, and generally consistent with the underlying patient population and background therapy. The five most common TEAEs were headache, pyrexia, COVID-19,
        nasopharyngitis, and upper respiratory&#160;tract infection.&#160;No&#160;deaths or suspected unexpected serious adverse reactions or hypersensitivity reactions were observed with apitegromab at 36 months. A total of 21 serious TEAEs were reported over the
        36-month treatment period. No patients displayed positive titers for apitegromab antibodies (ADA).</div>

      <div style="text-align: left;"><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">More than 90 percent of nonambulatory patients remained on treatment in the extension study.</div>

      <div><br />
      </div>

      <div><br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9.01. Financial Statements and Exhibits.</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(d) Exhibits</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 8.92%; vertical-align: middle; border-bottom: #000000 2px solid;">
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit</div>
              <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">No.</div>
            </td>

    <td style="width: 0.71%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 90.37%; vertical-align: bottom; border-bottom: #000000 2px solid;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.92%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 0.71%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 90.37%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.92%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53438186_ex991.htm">99.1</a></div>
            </td>

    <td style="width: 0.71%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 90.37%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53438186_ex991.htm">Press Release issued
                  by the Company on June 30, 2023.</a></div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.92%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53438186_ex992.htm">99.2</a></div>
            </td>

    <td style="width: 0.71%; vertical-align: middle;">&#160;</td>

    <td style="width: 90.37%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="#a53438186_ex992.htm">Presentation Slide
                  Deck</a></div>
            </td>

  </tr>

  <tr>

    <td style="width: 8.92%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
            </td>

    <td style="width: 0.71%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
            </td>

    <td style="width: 90.37%; vertical-align: middle;">
              <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      </div>

      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
        by the undersigned hereunto duly authorized.</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br />
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 52%;">
                <div>&#160;</div>
              </td>

    <td style="font-weight: bold;" rowspan="1" colspan="2">Scholar Rock Holding Corporation</td>

  </tr>

  <tr>

    <td style="width: 52%;">
                <div>&#160;</div>
              </td>

    <td style="width: 3%;">
                <div>&#160;</div>
              </td>

    <td style="width: 45%;">
                <div>&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 52%;">
                <div>&#160;</div>
              </td>

    <td style="width: 3%;">
                <div>&#160;</div>
              </td>

    <td style="width: 45%;">
                <div>&#160;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 52%; padding-bottom: 2px;">Date: June 30, 2023</td>

    <td style="width: 3%; padding-bottom: 2px;">By:<br />
              </td>

    <td style="width: 45%; color: rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">/s/ Junlin Ho</div>
              </td>

  </tr>

  <tr>

    <td style="width: 52%;">
                <div>&#160;</div>
              </td>

    <td style="width: 3%;">
                <div>&#160;</div>
              </td>

    <td style="width: 45%;">Junlin Ho</td>

  </tr>

  <tr>

    <td style="width: 52%;">
                <div>&#160;</div>
              </td>

    <td style="width: 3%;">
                <div>&#160;</div>
              </td>

    <td style="width: 45%;">General Counsel and Corporate Secretary</td>

  </tr>


</table>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>


    </div>

  </div>

</body>

<!-- Mirrored from investors.scholarrock.com/node/9561/html by HTTrack Website Copier/3.x [XR&CO'2014], Sat, 21 Dec 2024 12:08:01 GMT -->
</html>
</XBRL>
<div><a name="a53438186_ex991.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div class="bw-release">
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>New 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory</b>
        <b>Spinal Muscular Atrophy</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Improvements in patient-reported outcomes consistent with gains in motor function scores</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Safety profile at 36 months consistent with previous reports with no new safety findings; more than 90 percent of nonambulatory patients remained on study</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Enrollment progressing in pivotal Phase 3 SAPPHIRE registrational trial, anticipated completion in Q3 2023</i> </b></p>
        <p style="text-align: center; list-style-position: inside;"><b> - <i>Scholar Rock to host virtual investor event on July 12 at 9:00 AM EST to discuss the current SMA treatment landscape and apitegromab&#8217;s potential to advance the standard of care</i>
          </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 29, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today
            announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab. These data showed that continued treatment with apitegromab over the extended treatment period was
            associated with substantial and sustained improvement in motor function, as well as improvements in patient-reported outcome measures in patients with nonambulatory Types 2 and 3 spinal muscular atrophy (SMA) receiving survival motor neuron
            (SMN)-targeted therapy. Detailed results were presented today by Thomas Crawford, M.D., of Johns Hopkins Medicine, and the lead principal investigator of the TOPAZ trial, during two podium presentations at the Cure SMA Research &amp; Clinical
            Care Meeting in Orlando, Florida. </p>
          <p> &#8220;These promising long-term data highlight the therapeutic potential of muscle-targeted therapies, such as apitegromab, to help those with SMA address persistent weakness,&#8221; said Dr. Crawford. &#8220;While SMN-targeted therapies play an important
            role in preventing further loss of motor neurons, many people still experience persistent or progressive symptoms due to preexisting motor neuron degeneration. Incorporating a muscle-targeted therapy with apitegromab&#8217;s clinical profile into the
            treatment paradigm could allow patients to sustain or potentially achieve new gains in motor functioning.&#8221; </p>
          <p> &#8220;We are excited to share these new Phase 2 data that support apitegromab&#8217;s long-term durability of effect and consistent tolerability and safety profile. The results further strengthen our confidence in apitegromab&#8217;s therapeutic potential for
            patients with SMA, as well as validate Scholar Rock&#8217;s unique approach to selectively inhibiting the pro and latent forms of myostatin,&#8221; said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock. &#8220;In addition to the
            sustained benefit observed with consistent HFMSE scores, we saw continued improvement in RULM scores, and reductions in fatigue as reported by patients&#8212;all of which can be important factors in performing activities of daily living. We remain
            committed to advancing the standard of care for people with SMA, and we look forward to sharing updates on our pivotal Phase 3 SAPPHIRE trial, which we anticipate will complete enrollment in the third quarter of 2023.&#8221; </p>

          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Substantial and Sustained Gains in Motor Function Observed Over the Extended Treatment Period: </b>Nonambulatory patients (ages 2-21) experienced substantial and sustained gains in Hammersmith Functional Motor Scale-Expanded (HFMSE) and
            Revised Upper Limb Module (RULM) scores over the 36-month extended treatment period from baseline: </p>
          <table cellspacing="0" id="z11a348d6c55b49e99806327cb0517107" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;padding-left: 0px;background-color: #d3d3d3;">
                  <p style="margin-bottom: 0px; margin-top: 0px;"> &#160; </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;background-color: #d3d3d3;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>12</b>-<b>Month Data</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;background-color: #d3d3d3;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>24-Month Data</b> </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-top: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;background-color: #d3d3d3;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>36-Month Data</b> </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;text-align: left;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> <b>Mean Change from Baseline in HFMSE </b>(95% Confidence Interval) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>3.6 points</b> </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> (1.2, 6.0) </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> N=32 </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>4.2 points</b> </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> (1.9, 6.6) </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> N=29 </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>4.0 points</b> </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> (1.0, 6.9) </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> N=28 </p>
                </td>
              </tr>
              <tr>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;text-align: left;padding-left: 5px;">
                  <p style="margin-bottom: 0px; margin-top: 0px;text-align: left;"> <b>Mean Change from Baseline in </b><b>RULM </b>(95% Confidence Interval) </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>1.3 points</b> </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> (0.2, 2.3) </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> N=31 </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>2.3 points</b> </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> (1.2, 3.3) </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> N=31 </p>
                </td>
                <td colspan="1" rowspan="1" style="vertical-align: top;border-bottom: solid black 1pt;border-right: solid black 1pt;text-align: center; list-style-position: inside;padding-left: 5px;">
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> <b>2.4 points</b> </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> (1.1, 3.7) </p>
                  <p style="text-align: center; list-style-position: inside;margin-bottom: 0px; margin-top: 0px;"> N=27 </p>
                </td>
              </tr>

          </table>
          <p> For the 36-month data, an observed case analysis was conducted, which pooled data for all nonambulatory patients (including those patients on 20 mg/kg of apitegromab for the full duration of the trial, and those who switched from 2 mg/kg to
            20 mg/kg at various time intervals in year 2) and was based upon the available data. These analyses exclude data for patients post scoliosis surgery. </p>
          <p> <b>Improvement in Patient-Reported Outcomes Consistent with Improvements in Motor Function: </b>Nonambulatory patients (ages 2-21) had improvements in PEDI-CAT (measure of activities of daily living) and PROMIS-Fatigue (a patient-reported
            outcome tool measuring fatigue) that were consistent and sustained at 36 months. The mean change in PEDI-CAT daily activity domain from baseline at 36 months was 2.2 (95% CI: &#8211;0.1, 4.5; N=17), indicating an improvement in the ability to perform
            daily activities. The mean change in PROMIS-Fatigue from baseline at 36 months was &#8211;4.6 (95% CI: &#8211;8.7, &#8211;0.5; N=14), indicating a decline in fatigue. These improvements in PEDI-CAT and PROMIS-Fatigue were generally consistent with improvements
            in motor function across the 36 months of the study period. </p>
          <p> <b>Consistent Safety Data:</b> Treatment-emergent adverse events (TEAEs) at 36 months were consistent with previous reports at 12 and 24 months, with no new findings after an aggregate of 198 patient-years of exposure. TEAEs were mostly
            mild-to-moderate in severity, and generally consistent with the underlying patient population and background therapy. The five most common TEAEs were headache, pyrexia, COVID-19, nasopharyngitis, and upper respiratory tract infection. No deaths
            or suspected unexpected serious adverse reactions or hypersensitivity reactions were observed with apitegromab at 36 months. A total of 21 serious TEAEs were reported over the 36-month treatment period. No patients displayed positive titers for
            apitegromab antibodies (ADA). </p>
          <p> More than 90 percent of nonambulatory patients remained on treatment in the extension study. </p>
          <p> Details of the podium presentations at SMA Research &amp; Clinical Care Meeting are as follows: </p>
          <p> <b>Title:</b> Effect of apitegromab on PEDI-CAT and PROMIS-Fatigue questionnaire at 36 months in patients with Type 2 and nonambulatory Type 3 spinal muscular atrophy <br>
            <b>Presentation type:</b> Oral presentation <br>
            <b>Presenter:</b> Thomas O. Crawford, M.D., Professor of Neurology and Pediatrics, Johns Hopkins University <br>
            <b>Date and time:</b> Friday, June 30, 2023, 10:40 AM EST <br>
            <b>Location:</b> Disney Swan and Dolphin Hotels, Orlando, FL </p>

          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Title:</b> Effect of apitegromab on motor function at 36 months in patients with Type 2 and nonambulatory Type 3 spinal muscular atrophy <br>
            <b>Presentation type:</b> Oral presentation <br>
            <b>Presenter:</b> Thomas O. Crawford, M.D., Professor of Neurology and Pediatrics, Johns Hopkins University <br>
            <b>Date and time:</b> Friday, June 30, 2023, 11:00 AM EST <br>
            <b>Location:</b> Disney Swan and Dolphin Hotels, Orlando, Florida <br>
            For conference information, visit https://www.researchandclinicalcaremeeting.com/ </p>
          <p> The presentations will be made available in the Publications &amp; Posters section of Scholar Rock&#8217;s website following the presentation. </p>
          <p> <b>Conference Call/Webcast:</b> </p>
          <p> Scholar Rock will host a virtual investor event on July 12 at 9:00 AM EST to discuss the current SMA treatment landscape and apitegromab&#8217;s potential to advance the standard of care for patients with nonambulatory Types 2 and 3 SMA<i>. </i>Click
            here to register and listen to the webcast.<i> </i>A link to the webcast of this event is also available on the Investors &amp; Media section of the Scholar Rock website at http://investors.scholarrock.com. </p>
          <p> An archived replay of the webcast will be available on Scholar Rock&#8217;s website at: https://scholarrock.com/ for approximately 90 days following the presentation. </p>
          <p> <b>About the Phase 2 TOPAZ Trial</b> </p>
          <p> The TOPAZ trial is an ongoing proof-of-concept, open-label Phase 2 trial evaluating the safety and efficacy of apitegromab in patients with Types 2 and 3 SMA. In the main treatment period, patients were dosed intravenously every four weeks as
            monotherapy or with nusinersen, an approved SMN-targeted therapy. The trial enrolled 58 patients in the U.S. and Europe. The primary efficacy endpoints were mean change from baseline in Revised Hammersmith Scale (RHS) score at 12 months for the
            ambulatory population (Cohort 1), and mean change from baseline in HFMSE score at 12 months for the nonambulatory population (Cohorts 2 and 3). The trial also includes multiple 12-month extension periods designed to evaluate longer-term patient
            outcomes. </p>
          <p> <b>About the Phase 3 SAPPHIRE Trial</b> </p>
          <p> SAPPHIRE is an ongoing randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 SMA who are receiving SMN therapy (either nusinersen or
            risdiplam). Approximately 156 patients aged 2-12 years old are anticipated to be enrolled in the main efficacy population. These patients will be randomized 1:1:1 to receive for 12 months either apitegromab 10 mg/kg, apitegromab 20 mg/kg, or
            placebo by intravenous (IV) infusion every 4 weeks. An exploratory population of approximately 48 patients aged 13-21 years old will also separately be evaluated. These patients will be randomized 2:1 to receive either apitegromab 20 mg/kg or
            placebo. For more information about SAPPHIRE, visit www.clinicaltrials.gov. </p>

          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>About Apitegromab</b> </p>
          <p> Apitegromab is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is the first muscle-targeted treatment candidate to
            demonstrate clinical proof of concept in spinal muscular atrophy (SMA). Myostatin, a member of the TGF&#946; superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase
            in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that our highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor
            function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan
            Medicinal Product designations, to apitegromab for the treatment of SMA. The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any use by the FDA or any other regulatory agency. </p>
          <p> <b>About SMA</b> </p>
          <p> Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease that afflicts an estimated 30,000 to 35,000 people in the United States and Europe. The disease is characterized by the loss of motor neurons, atrophy of the voluntary
            muscles of the limbs and trunk, and progressive muscle weakness. While there has been progress in the development of therapeutics that address the loss of motor neurons, there continues to be a high unmet need for therapies that directly
            address the progressive muscle weakness that leads to loss of motor function in SMA. </p>
          <p> <b>About Scholar Rock</b> </p>
          <p> Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar
            Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock&#8217;s approach to
            targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular
            level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on
            biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn
            (https://www.linkedin.com/company/scholar-rock/). </p>

          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> <b>Availability of Other Information About Scholar Rock</b> </p>
          <p> Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange
            Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material
            information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any
            filing under the Securities Act of 1933, as amended. </p>
          <p> Scholar Rock&#174; is a registered trademark of Scholar Rock, Inc. </p>
          <p> <b>Forward-Looking Statements</b> </p>
          <p> This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock&#8217;s future expectations, plans and prospects,
            including without limitation, Scholar Rock&#8217;s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, and other product candidates and indication selection and development timing, the ability of
            any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform.<i> </i>The use of words such as &#8220;may,&#8221;
            &#8220;might,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify such forward-looking statements. All
            such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or
            implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 clinical trial of apitegromab, and are not predictive of, may be
            inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidates, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA , Scholar Rock&#8217;s ability to provide the
            financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, information provided or
            decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, Scholar Rock&#8217;s dependence on third parties
            for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional funding when needed to support its business activities and
            establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk
            Factors" in Scholar Rock&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and
            Exchange Commission. Any forward-looking statements represent Scholar Rock&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of
            the release, and Scholar Rock undertakes no duty to update this information unless required by law. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> <b>Scholar Rock:</b> </p>
          <p> <b>I</b><b>nvestors </b><br>
            Rushmie Nofsinger <br>
            Scholar Rock <br>
            rnofsinger@scholarrock.com<br>
            ir@scholarrock.com<br>
            857-259-5573 </p>
          <p> <b>Media </b><br>
            Teagan White <br>
            Finn Partners <br>
            teagan.white@finnpartners.com<br>
            media@scholarrock.com<br>
            650-766-3955 </p>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
<div><a name="a53438186_ex992.htm"></a></div><html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.2<br>
    </font></div>
  <div style="text-align: left;"><font style="font-weight: bold;"><br>
    </font></div>
  <div style="text-align: center;"><font style="font-weight: bold;">
      <title></title>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide1.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Deep InsightsAdvancingImpactful Medicines&#160;&#160;Company Overview | June 2023 &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide2.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;&#169; Scholar Rock, Inc. All rights reserved. 2023. &#160;&#160;Forward-Looking
              Statements&#160;&#160;Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. (&#8220;Scholar Rock&#8221;), including without limitation, Scholar Rock&#8217;s expectations regarding its strategy, its product
              candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for apitegromab, SRK-181, and other product candidates and indication selection and development timing, its cash
              runway, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such
              as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;future,&#8221; &#8220;potential,&#8221; or &#8220;continue,&#8221; and other similar expressions are intended to identify such forward-looking
              statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. All such forward-looking statements are based on management's current expectations of future events and are subject to a
              number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that
              preclinical and clinical data, including the results from the Phase 2 trial of apitegromab or Part A of the Phase 1 trial of SRK-181, are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical
              trials of the same product candidate, including the Phase 3 clinical trial of apitegromab in SMA and Part B of the Phase 1 clinical trial of SRK-181, respectively,&#160;Scholar Rock&#8217;s ability to provide the financial support, resources and
              expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock&#8217;s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory
              authorities,&#160;competition from third parties that are developing products for similar uses, Scholar Rock&#8217;s ability to obtain, maintain and protect its intellectual property, the success of Scholar Rock&#8217;s current and potential future
              collaborations, Scholar Rock&#8217;s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock&#8217;s ability to manage expenses and to obtain additional
              funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of current macroeconomic and geopolitical events, hostilities in Ukraine, increasing
              rates of inflation and rising interest rates, on business operations and expectations, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock&#8217;s Quarterly Report on Form 10-Q for the quarter ended
              March 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock&#8217;s subsequent filings with the Securities and Exchange Commission.&#160; Any forward-looking statements represent Scholar Rock&#8217;s
              views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information
              unless required by law.&#160;Apitegromab&#160;and SRK-181 are investigational drug candidates under evaluation.&#160; Apitegromab and SRK-181 have not been approved for any use by the FDA or any other regulatory agency and the safety and efficacy of
              apitegromab and SRK-181 have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide3.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Scholar Rock: Transforming Patient Lives, Addressing High Unmet Medical
              Need&#160;&#160;3&#160;&#160;Global leader in TGF&#946; superfamily biology&#160;&#160;&#160;Targeting the latent forms of growth factors&#160;&#160;&#160;Exquisite selectivity to deliver differentiated therapies&#160;&#160;&#160;Revolutionary Platform&#160;&#160;Rich preclinical pipeline focused on high unmet patient
              needs&#160;&#160;&#160;Phase 3 SAPPHIRE study underway, enrollment completion expected in Q3 2023; data readoutexpected in 2024 &#160;&#160;Phase 1 proof-of-concept DRAGON study underway in immuno-oncology &#160;&#160;Neuromuscular and Beyond&#160;&#160;Compelling proof-of-concept TOPAZ
              data informed Phase 3 SAPPHIRE study design&#160;&#160;Seasoned leadership team with track record of clinical and commercial success &#160;&#160;Anticipated cash runway into 2025&#160;&#160;Positioned&#160;&#160;for Success&#160;&#160;Commercial planning underway for apitegromab (SMA) in US
              and Europe&#160;&#160;&#160;Broad platform, including promising early-stage assets, provides opportunities to advance alone or in partnership&#160;&#160;Strategic Optionality &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide4.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Revolutionary Approach to Regulating TGF&#946; Superfamily Implicated in Devastating
              Diseases&#160;&#160;4&#160;&#160;Scholar Rock&#8217;s R&amp;D Platform&#160;&#160;Transforming Medical Practice&#160;&#160;Selectively target the latent form of growth factors in the microenvironment of cells and tissues with uniquely designed antibodies&#160;&#160;Overcome the challenges that
              plague traditional approaches that target the &#8220;mature&#8221; growth factor or its receptors, which are difficult to differentiate and lead to unintended negative effects&#160;&#160;Scholar Rock&#8217;s TargetLatent Growth Factor&#160;&#160;Traditional Target&#8220;mature&#8221; growth
              factor&#160;&#160;TGF&#946; Superfamily: Highly Sought-After Targets &#160;&#160;Dysregulation plays a role in devastating diseases that have a high unmet need, including:&#160;&#160;Neuromuscular disorders &#160;&#160;&#160;Fibrosis&#160;&#160;Oncology&#160;&#160;Recognized by the industry as important targets
              given their fundamental roles in regulating a variety of biological processes&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide5.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;DISCOVERY/PRECLINICAL&#160;&#160;PHASE 1&#160;&#160;PHASE 2&#160;&#160;PHASE 3&#160;&#160;ANTICIPATED 2023
              MILESTONES&#160;&#160;SPINAL MUSCULAR ATROPHYApitegromab (selective anti- pro and latent myostatin)&#160;&#160;36-month TOPAZ data&#160;&#160;SAPPHIRE: last patient enrolled expected in Q3&#160;&#160;IMMUNO-ONCOLOGYSRK-181 (selective context-independent, anti-latent
              TGF&#946;-1)&#160;&#160;Rolling clinical data updates&#160;&#160;ANEMIASelective anti-RGMc&#160;&#160;IND-enabling studies&#160;&#160;FIBROSIS&#160;&#160;Selective context-dependent (LTBP1 &amp; LTBP3) anti-latent TGF&#946;-1&#160;&#160;&#160;IND-enabling studies&#160;&#160;Robust Pipeline of Novel Product Candidates
              &#160;&#160;5&#160;&#160;Potential to transform the lives of people living with awide range of serious diseases, including neuromuscular disorders, oncology, and fibrosis&#160;&#160;LTBP3=latent transforming growth factor beta binding protein 3; LTBP1=Latent Transforming
              Growth Factor Beta Binding Protein 1; RGM=Repulsive guidance molecule; TGF&#946;-1&#160;=Transforming Growth Factor Beta-1&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide6.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Leadership Team: Experienced in Drug Development and Commercialization&#160;&#160;6&#160;&#160;Jay
              Backstrom, MD, MPH&#160;&#160;President &amp; CEO&#160;&#160;30 years of clinical R&amp;D experience, leading multiple successful regulatory approvals&#160;&#160;Ted Myles, MBA&#160;&#160;Chief Operating Officer &amp; CFO&#160;&#160;25 years of progressive experience in clinical and
              commercial-stage companies &#160;&#160;25 years of experience leading HR, culture transformation, leadership development, DEI, and talent management&#160;&#160;Caryn Parlavecchio&#160;&#160;Chief Human Resources Officer&#160;&#160;15 years of experience leading and advising life
              sciences companies in areas of legal and compliance &#160;&#160;Junlin Ho, JD&#160;&#160;General Counsel &amp;Corporate Secretary&#160;&#160;Mo Qatanani, PhD&#160;&#160;SVP, Research&#160;&#160;15 years of industry experience on the strategic and operational sides of research &amp;
              development&#160;&#160;Tracey Sacco&#160;&#160;Chief Commercial Officer&#160;&#160;20 years of commercial leadership experience, including product launch and global commercial strategy&#160;&#160;Jing Marantz, MD, PhD&#160;&#160;Chief Medical Officer &#160;&#160;20 years of development and medical
              leadership experience across neurology, hematology/oncology, and rare diseases&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide7.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Apitegromab: The Next Potential Transformative Therapy for Patients with Spinal
              Muscular Atrophy (SMA)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide8.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Apitegromab: Transformative Potential to Change the Standard of
              Care&#160;&#160;8&#160;&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy (SMA). Apitegromab has not been approved for any use by the FDA or any other regulatory agency, and its safety and efficacy
              have not been established.&#160;&#160;Phase 2 TOPAZ TrialDemonstrated substantial and sustained functional improvements in Type 2 and nonambulatory Type 3 SMA patients&#160;&#160;Apitegromab at a Glance &#160;&#160;First and only muscle-targeted investigational treatment
              to demonstrate clinical proof-of-concept in SMA&#160;&#160;Phase 3 SAPPHIRE TrialRegistrational trial with topline 12-month data readout expected in 2024&#160;&#160;ONYX Open-Label Extension Study Evaluating the long-term safety and efficacy of apitegromab in
              patients who have completed TOPAZ or SAPPHIRE &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide9.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;There is further potential to regain vital muscle function by also addressing
              the progressive muscle atrophy and associated weakness of SMA &#160;&#160;SMN therapies slow further degeneration of motor neurons1&#160;&#160;Hallmarks of SMAProgressive Motor Neuron Loss and&#160;Muscle Atrophy Leading to Progressive Muscle Weakness&#160;&#160;&#160;9&#160;&#160;SMA,
              spinal muscular atrophy; SMN, survival motor neuron.1. Hua Y, et al. Nature. 2011;478(7367):123-6. 2. Figure adapted from: SMA Foundation Overview. http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf.;&#160;Accessed April 18,
              2021. &#160;&#160;...but do not directly address muscle atrophy&#160;&#160;Muscle fiber atrophy&#160;&#160;Motor neuron&#160;&#160;degeneration2&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide10.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;10&#160;&#160;*TOPAZ Phase 2 trial evaluated patients with Type 2 and 3 SMA (did not
              include Type 1)&#160;&#160;** 2/3 of overall patient population has type 2 or 3 SMA, including ambulatory and nonambulatory patients. Percentages reflected here do not add up to 100% because the prevalences of Types 0, 4, and unknown are
              excluded.&#160;&#160;Percentages represent percent of prevalent patients.&#160;&#160;1. Lally et al, Orphanet Journal of Rare Diseases, 2017; 2. SMA Europe. SMATracker. About SMA. Accessed January 24, 2022. https://smatracker.eu/what-is-spinal-muscular-atrophy;
              3. National Organization for Rare Disorders. Spinal muscular atrophy. Accessed January 24, 2022. https://rarediseases.org/rare-diseases/spinal-muscular-atrophy/. 4. Cure SMA. Care Series Booklet. Accessed September 19, 2021. 2020.
              https://www.curesma.org/wpcontent/uploads/2020/08/08262020_Understanding_SMA_vWeb.pdf. 5. Cure SMA. State of SMA 2022. May 31, 2022. https://www.curesma.org/wp-content/uploads/2022/06/9042022_State-of-SMA_vweb.pdf Apitegromab is an
              investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been
              established.&#160;&#160;Severe, progressive disabilities; unable to walk independently&#160;&#160;Significant, progressive motor function impairment; many lose ambulation&#160;&#160;Infant onset; unable to sit up independently&#160;&#160;Type 3&#160;&#160;25%&#160;&#160;Type 2&#160;&#160;39%&#160;&#160;Type
              1&#160;&#160;25%&#160;&#160;TOPAZ* 12-month results showed transformative potential in nonambulatory Types 2 and 3 patients&#160;&#160;~2/3 of overall &#160;&#160;patient population5**&#160;&#160;GLOBAL DISEASE:&#160;&#160;30,000-35,000 affected in US and Europe1, 2, 3,4&#160;&#160;Cure SMA. State of SMA 2022.
              May 31, 2022&#160;&#160;ALMOST 70% OF INDIVIDUALS WITH SMA IN THE U.S. HAVE RECEIVED AN FDA-APPROVED TREATMENT &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide11.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Motor Function With SMN Therapies as Assessed by HFMSE HFMSE appears to Plateau
              After Initial Gains&#160;&#160;1. Mercuri E, et al. Presented at: World Muscle Society Congress 2020, P. 257&#160;&#160;2. Oskoui M, et al. Presented at: 2021 Muscular Dystrophy Association Clinical &amp; Scientific Conference; March 15-18, 2021. Poster 80.
              &#160;&#160;HFMSE, Hammersmith Functional Motor Scale&#8211;Expanded; SE, standard error.&#160;&#160;*MFM was primary efficacy endpoint of SUNFISH. HFMSE was a secondary endpoint. This third-party information is provided for background only and is not intended to
              convey or imply a comparison to the TOPAZ clinical trial results. &#160;&#160;Overall population age 2-25 &#160;&#160;Change in HFMSE* Over Four Years with Risdiplam2
              &#160;&#160;Risdiplam&#160;&#160;n=&#160;&#160;120&#160;&#160;120&#160;&#160;119&#160;&#160;117&#160;&#160;109&#160;&#160;106&#160;&#160;89&#160;&#160;99&#160;&#160;101&#160;&#160;97&#160;&#160;Placebo&#160;&#160;n=&#160;&#160;60&#160;&#160;60&#160;&#160;58&#160;&#160;58&#160;&#160;Risdiplam&#160;&#160;Placebo (months 0-12)&#160;&#160;Mean (+/-SE) Change in HFMSE&#160;&#160;Total Score From Baseline*&#160;&#160;0&#160;&#160;30&#160;&#160;48&#160;&#160;6&#160;&#160;12&#160;&#160;18&#160;&#160;24&#160;&#160;36&#160;&#160;42&#160;&#160;Visit,
              months&#160;&#160;11&#160;&#160;Change in HFMSE Over Four Years with Nusinersen1 &#160;&#160;Overall population age 2-12 &#160;&#160;Mean (+SE) Change in HFMSE&#160;&#160;Total Score From Baseline&#160;&#160;Analysis Visit, days&#160;&#160;Initial Treatment&#160;&#160;CHERISH&#160;&#160;Chronic Maintenance
              Phase&#160;&#160;SHINE&#160;&#160;1&#160;&#160;92&#160;&#160;169&#160;&#160;253&#160;&#160;350&#160;&#160;450&#160;&#160;690&#160;&#160;930&#160;&#160;1170&#160;&#160;1410&#160;&#160;1650&#160;&#160;Nusinersen&#160;&#160;n=&#160;&#160;84&#160;&#160;82&#160;&#160;84&#160;&#160;84&#160;&#160;83&#160;&#160;76&#160;&#160; 83&#160;&#160; 83&#160;&#160; 79&#160;&#160; 61&#160;&#160; 20&#160;&#160;Placebo&#160;&#160;n=&#160;&#160;42&#160;&#160;41&#160;&#160;41&#160;&#160;42&#160;&#160;42&#160;&#160;39&#160;&#160;Nusinersen in CHERISH and SHINE&#160;&#160;Sham control in CHERISH&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide12.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Patients and caregivers want new therapies to address the following unmet
              needs2* : &#160;&#160;Improving and Sustaining Muscle Function Remains an Unmet Need&#160;&#160;12&#160;&#160;HFMSE=Hammersmith Functional Motor Scale-Expanded &#160;&#160;*Percentages represent percent of patients who named these unmet needs when asked &#8220;What are your most
              significant current unmet needs that you hope new therapies would address&#8221;?&#160;&#160;1. Mercuri E et al.;&#160;N Engl J Med 2018; 378:625-635; DOI: 10.1056/NEJMoa1710504; cherish trial results. 2. 2022 Community Update Survey, Cure SMA.This third-party
              information is provided for background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results.&#160;&#160;Mean improvement in HFMSE experienced by patients with&#160;&#160;nonambulatory Types 2/3 SMA in nusinersen Phase 3
              CHERISH trial1&#160;&#160;3.9-point increase in HFMSE from nusinersen(4.9 point increase relative to sham control)&#160;&#160;HFMSE Score at Month 15&#160;&#160;Total Possible HFMSE Score of 66&#160;&#160;Unmet need remains substantial &#160;&#160;Increase muscle strength &#160;&#160;Improve daily
              activities &#160;&#160;Stabilize or gain new motor function &#160;&#160;Reduce fatigue &#160;&#160;97%&#160;&#160;92%&#160;&#160;89%&#160;&#160;83%&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide13.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Apitegromab Offers Significant Potential to Address Unmet Needs &#160;&#160;13&#160;&#160;*&#160;Based on
              Animal Model Data; 1. Long KK, et al. Hum Mol Genet. 2019;28(7):1077-1088; 2. Pirruccello-Straub M, et al. Sci Reports. 2018;8(1):2292. doi:10.1038/s41598-018-20524-9 3. Figure adapted from: SMA Foundation Overview.
              http://www.smafoundation.org/wp-content/uploads/2012/03/SMA-Overview.pdf.;&#160;Accessed April 18, 2021. For illustrative purposes only&#160;&#160;Apitegromab is a&#160;&#160;MUSCLE-TARGETED APPROACH&#160;&#160;designed to improve motor function*1,2&#160;&#160;Myostatin is a negative
              modulator of muscle growth &#160;&#160;Strong preclinical evidence indicates upstream targeting of structurally differentiated pro- and latent myostatin avoids undesirable off-target effects&#160;&#160;Apitegromab&#160;&#160;Muscle fiber atrophy&#160;&#160;Apitegromab selectively
              inhibits myostatin and has the potential to build muscle and strength to improve certain patient outcomes&#160;&#160;Motor neuron&#160;&#160;degeneration3&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide14.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Phase 2 TOPAZ Trial: Safety and Efficacy Data from First Muscle-Targeted
              Treatment Candidate in SMA&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide15.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Phase 2 Trial Design1,2&#160;&#160;15&#160;&#160;Ambulatory Patients (Revised Hammersmith
              Scale)&#160;&#160;Safety&#160;&#160;RHS mean change from baseline at 12 months&#160;&#160;Ages 5-21&#160;&#160;Type 3 SMA&#160;&#160;Open-label, single-arm&#160;&#160;Apitegromab 20 mg/kg IV q4w&#160;&#160;Receiving nusinersen&#160;&#160;Apitegromab monotherapy&#160;&#160;Nonambulatory Patients (Hammersmith Functional Motor Scale
              Expanded)&#160;&#160;Safety&#160;&#160;HFMSE mean change from baseline at 12 months&#160;&#160;COHORT 2 N=15&#160;&#160;Ages 5-21&#160;&#160;Type 2 or Type 3 SMA&#160;&#160;Apitegromab 20 mg/kg IV q4w&#160;&#160;Open-label, single-arm&#160;&#160;Receiving nusinersen&#160;&#160;(initiated &#8805; 5 years of age)&#160;&#160;Safety&#160;&#160;HFMSE mean
              change from baseline at 12 months&#160;&#160;COHORT 3 N=20&#160;&#160;Ages &#8805; 2&#160;&#160;Type 2 SMA&#160;&#160;&#160;Apitegromab 2 mg/kg IV q4w&#160;&#160;Apitegromab 20 mg/kg IV q4w&#160;&#160;R1:1&#160;&#160;Double-blind, randomized (1:1)&#160;&#160;Receiving nusinersen &#160;&#160;(initiated&lt; 5 years of age)&#160;&#160;TREATMENT (12
              months)&#160;&#160;PRIMARY ENDPOINTS&#160;&#160;All SMA Types 2/3, cohorts defined by age and present ambulatory status at time of enrollment. HFMSE, Hammersmith Functional Motor Scale Expanded; IV, intravenous; q4w, every 4 weeks; SMA, spinal muscular atrophy;
              SMN, survival motor neuron. &#160;&#160;1. Place A, et al. Eu J Neurol. 2021;28(Suppl1):207-334 (EPR-184). 2. Crawford T, et al. TOPAZ Extension: 24-month Efficacy and Safety of Apitegromab in Patients With Later-onset SMA (Type 2 and Type 3 SMA).
              Presented at CureSMA Annual Conference; June 16-19, 2022.&#160;&#160;COHORT 1 N=23&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide16.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Motor Function Outcomes by HFMSE Over 36 Months Improvements Were Substantial
              and Sustained &#160;&#160;16&#160;&#160;For the 36-month evaluation, an observed case analysis was conducted, which pooled all the nonambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis population
              included patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). This analysis excludes data post scoliosis surgery from seven
              patients. One patient did not conduct HFMSE at time of database lock for 24 months, however, this patient had an unscheduled HFMSE score one month prior to their scheduled visit. In the most recent analysis, this result was included in the
              24-month analysis. Error bars represent SE. CI represents confidence interval. SMN Rx=SMN therapy. In the age 2-21 group, 18/28 patients achieved&#160;&#8805;&#160;1-pt gains, and 11/28 patients&#160;&#8805; 3-pt gains at 36 months.&#160;Data cutoff date as of March 13,
              2023. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have
              not been established.&#160;&#160;n=&#160;&#160;35&#160;&#160;29&#160;&#160;32&#160;&#160;29&#160;&#160;28&#160;&#160;95% CI=&#160;&#160;(1.4,&#8201;4.1)&#160;&#160;(1.2,&#8201;6.0)&#160;&#160;(1.9,&#8201;6.6)&#160;&#160;(1.0,&#8201;6.9)&#160;&#160;n=&#160;&#160;29&#160;&#160;23&#160;&#160;26&#160;&#160;23&#160;&#160;23&#160;&#160;95% CI=&#160;&#160;(1.8,&#8201;5.0)&#160;&#160;(1.8,&#8201;7.4)&#160;&#160;(2.3,&#8201;8.0)&#160;&#160;(1.3,&#8201;8.3)&#160;&#160;Pooled Nonambulatory Patients &#160;&#160;Mean Change from Baseline
              (+SE)&#160;&#160;Baseline mean age=7.3 |&#8202;Time on SMN Rx=24.1m&#160;&#160;Age 2-21 YearsAll Doses (N=35)&#160;&#160;Baseline mean age=5.5 |&#8202;Time on SMN Rx=24.6m &#160;&#160;Age 2-12 YearsAll Doses (N=29)&#160;&#160;Mean Change from Baseline (+SE)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide17.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Motor Function Outcomes by RULM Over 36 Months Improvements Were Substantial and
              Sustained&#160;&#160;17&#160;&#160;For the 36-month evaluation, an observed case analysis was conducted, which pooled all the nonambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis population included
              patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). This analysis excludes data post scoliosis surgery from seven patients. One
              patient did not conduct RULM at month 24, however, had an unscheduled RULM score one month prior to their scheduled visit. In the most recent analysis, this result was included in the 24-month analysis. Error bars represent standard error
              (SE). CI represents confidence interval. SMN Rx=SMN therapy. In the age 2-21 group, 15/27 patients achieved&#160;&#8805;&#160;1-pt gains, and 18/27 patients&#160;&#8805; 3-pt gains at 36 months.&#160;Data cutoff date as of March 13, 2023. Apitegromab is an investigational
              drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Baseline mean
              age=7.3 |Time on SMN Rx=24.1m &#160;&#160;Baseline mean age=5.5 |Time on SMN Rx=24.6m &#160;&#160;Pooled Nonambulatory Patients &#160;&#160;Mean Change from Baseline (+SE)&#160;&#160;Age 2-21 YearsAll Doses (N=35)&#160;&#160;Age 2-12 YearsAll Doses (N=29)&#160;&#160;n=&#160;&#160;35&#160;&#160;28&#160;&#160;31&#160;&#160;31&#160;&#160;27&#160;&#160;95%
              CI=&#160;&#160;(-0.2, 1.4)&#160;&#160;(0.2, 2.3)&#160;&#160;(1.2, 3.3)&#160;&#160;(1.1, 3.7)&#160;&#160;n=&#160;&#160;29&#160;&#160;22&#160;&#160;25&#160;&#160;25&#160;&#160;22&#160;&#160;95% CI=&#160;&#160;(-0.7, 1.1)&#160;&#160;(0.1, 2.4)&#160;&#160;(1.0, 3.5)&#160;&#160;(1.4, 4.2)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide18.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Time (weeks)&#160;&#160;No. of observations&#160;&#160;Time (weeks)&#160;&#160;No. of observations&#160;&#160;Year
              3&#160;&#160;Year 2&#160;&#160;Year 1&#160;&#160;Pooled Nonambulatory Patients | Age 2 &#8211; 21 | All Doses | Over 36 Months Improvements in PRO Measures Were Consistent with Motor Function&#160;&#160;IMPROVEMENT&#160;&#160;PEDI-CAT Daily Activities&#160;&#160;IMPROVEMENT&#160;&#160;IMPROVEMENT&#160;&#160;N = 35; Baseline
              mean age=7.3 |Time on SMN Rx=24.1m &#160;&#160;HFMSE&#160;&#160;Change from baseline (&#177;SE)&#160;&#160;IMPROVEMENT&#160;&#160;Year 2&#160;&#160;Year 3&#160;&#160;Year 1&#160;&#160;RULM&#160;&#160;Year 3&#160;&#160;Year 2&#160;&#160;Year 1&#160;&#160;PROMIS Fatigue (Proxy)&#160;&#160;Change from baseline (&#177;SE)&#160;&#160;Year 2&#160;&#160;Year 3&#160;&#160;Year
              1&#160;&#160;34&#160;&#160;34&#160;&#160;34&#160;&#160;28&#160;&#160;27&#160;&#160;29&#160;&#160;31&#160;&#160;32&#160;&#160;32&#160;&#160;31&#160;&#160;27&#160;&#160;27&#160;&#160;27&#160;&#160;35&#160;&#160;35&#160;&#160;34&#160;&#160;29&#160;&#160;28&#160;&#160;29&#160;&#160;32&#160;&#160;32&#160;&#160;32&#160;&#160;29&#160;&#160;27&#160;&#160;28&#160;&#160;27&#160;&#160;31&#160;&#160;29&#160;&#160;30&#160;&#160;21&#160;&#160;23&#160;&#160;25&#160;&#160;25&#160;&#160;22&#160;&#160;27&#160;&#160;23&#160;&#160;16&#160;&#160;17&#160;&#160;15&#160;&#160;25&#160;&#160;23&#160;&#160;22&#160;&#160;19&#160;&#160;19&#160;&#160;22&#160;&#160;16&#160;&#160;19&#160;&#160;18&#160;&#160;19&#160;&#160;16&#160;&#160;14&#160;&#160;14&#160;&#160;HFMSE=Hammersmith Functional
              Motor Scale Expanded; OC=observed case; PEDI-CAT=Pediatric Evaluation of Disability Inventory Computer Adaptive Test; PROMIS=Patient Reported Outcome Measurement Information System; RULM=Revised upper limb module; SE=standard error of the
              mean. SMN Rx=SMN therapy. Data on File. Scholar Rock, Inc. Cambridge, MA. Data cutoff date as of March 13, 2023. The updated PEDI-CAT analysis included additional records (2 at 12 months and 1 at 24 months) that were not available at the time
              of previous analysis. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and
              efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide19.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Pooled Nonambulatory Patients New WHO Development Milestones Achieved Over 36
              Months &#160;&#160;19&#160;&#160;Proportion of patients gaining new milestones in TOPAZ&#160;&#160;Cohort 2: BL (0%),12m (20%), 24m (7%), 36m (0%)&#160;&#160;Cohort 3 (all doses): BL (0%,) 12m (24%), 24m (26%), 36m (30%)&#160;&#160;Cohort 3: Randomized to 20mg/kg dose: 12m (25%), 24m (33%),
              36m (40%)&#160;&#160;*Includes patients who crossed over from 2 mg/kg to 20mg/kg starting week 68 through week 104. &#160;&#160;SMN Rx=SMN therapy. Data cutoff date as of March 13, 2023. Apitegromab is an investigational drug candidate being evaluated for the
              treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Age (years)&#160;&#160;Hands &amp; kneescrawling&#160;&#160;Standing
              with&#160;&#160;assistance&#160;&#160;Walking with&#160;&#160;assistance&#160;&#160;Standing alone&#160;&#160;Walking&#160;&#160;alone&#160;&#160;SMN Rx (&#8805; age 5)&#160;&#160;8&#160;&#160;&#160;&#160;&#160;9&#160;&#160;&#160;&#160;&#160;19&#160;&#160;SMN Rx&#160;&#160;(&lt; age 5)&#160;&#160;2*&#160;&#160;4*&#160;&#160;&#160;&#160;&#160;5*&#160;&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;&#160;2&#160;&#160;&#160;&#160;&#160;4&#160;&#160;&#160;&#160;&#160;5&#160;&#160;WHO MILESTONE&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;
              &#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;Key Takeaways&#160;&#160;Patients receiving nusinersen &#8805; age 5 mostly maintained WHO milestones&#160;&#160;Patients receiving nusinersen &lt; age 5 improved overall: 6 out of 20 gained new milestones over 36
              months&#160;&#160;BL&#160;&#160;12M&#160;&#160;24M&#160;&#160;36M&#160;&#160;Able&#160;&#160;X&#160;&#160;Unable&#160;&#160;No record&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide20.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ Safety Summary Over 36 Months&#160;&#160;20&#160;&#160;Treatment-Emergent Adverse Events
              (TEAEs)*&#160;&#160;2 mg/kg dose &#160;&#160;(N=10)&#160;&#160;n (%)&#160;&#160;20 mg/kg dose &#160;&#160;(N=48)&#160;&#160;n (%)&#160;&#160;Total&#160;&#160;(N=58)&#160;&#160;n (%)&#160;&#160;Any TEAE&#160;&#160;10 (100)&#160;&#160;46 (95.8)&#160;&#160;56 (96.6)&#160;&#160;Any serious TEAE&#160;&#160;5 (50)&#160;&#160;16 (33.3)&#160;&#160;21 (36.2)&#160;&#160;Any TEAE leading to study drug discontinuation&#160;&#160;0&#160;&#160;1
              (2.1)&#160;&#160;1 (1.7)&#160;&#160;Any Grade 3 (severe) or higher TEAE&#160;&#160;4 (40)&#160;&#160;16 (33.3)&#160;&#160;20 (34.5)&#160;&#160;*Defined as AEs that start after the first dose of study drug or start prior to the administration of study drug and worsen in severity/grade or relationship
              to investigational medication after the administration of study drug. % = 100 x n/N; % at 12 month. AE, adverse event; TEAE, treatment emergent adverse events. Data cutoff date as of March 13, 2023. Apitegromab is an investigational drug
              candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;TEAEs were consistent
              with previous reports with no new findings after 198 patient-years of exposure&#160;&#160;Most frequently reported TEAEs*:&#160;headache (38%), pyrexia (38%), COVID-19 (36%), nasopharyngitis (36%), &amp; upper respiratory tract infection (33%)&#160;&#160;TEAEs were
              mostly mild to moderate in severity and generally consistent with the underlying patient population and nusinersen therapy&#160;&#160;No deaths or suspected unexpected serious adverse reactions or hypersensitivity reactions to apitegromab were
              reported&#160;&#160;No patients displayed positive titers for apitegromab antibodies (ADA)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide21.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Summary of TOPAZ Data&#160;&#160;Substantial and Sustained Improvement Over 36
              MONTHS&#160;&#160;21&#160;&#160;PRO=Patient Reported Outcome&#160;&#160;Data to date has shown substantial clinical benefit that is dose-dependent&#160;&#160;TOPAZ data suggest that apitegromab has the potential to transform care in SMA by directly addressing progressive muscle
              weakness&#160;&#160;Benefit continued to improve or was sustained&#160;over 36 months&#160;&#160;Consistency across functional scales and patient-reported outcomes&#160;&#160;Well tolerated profile and low discontinuation rate supports durability of treatment &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide22.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Sapphire Phase 3 Pivotal Trial&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide23.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SAPPHIRE Phase 3 Design is Optimized by Insights from TOPAZ&#160;&#160;23&#160;&#160;Substantial
              HFMSE gains observed in the nonambulatory Type 2/3 SMA cohorts&#160;&#160;Exploratory age 2-12 analysis in nonambulatory&#160;&#160;Type 2/3 showed transformative potential&#160;&#160;HFMSE gains substantial by 12 months of treatment&#160;&#160;Dose response seen&#160;&#160;(greater effect
              observed with 20 mg/kg over 2 mg/kg)&#160;&#160;Study population: nonambulatory Type 2/3 SMA&#160;&#160;Primary efficacy endpoint: HFMSE&#160;&#160;Age 2-12 main efficacy population&#160;&#160;12-month treatment duration&#160;&#160;20 mg/kg apitegromab dose&#160;&#160;Also evaluating 10 mg/kg arm (to
              explore potential that dose between 2 and 20 mg/kg may be comparable to 20 mg/kg)&#160;&#160;TOPAZ Learnings&#160;&#160;SAPPHIRE Design Elements&#160;&#160;HFMSE=Hammersmith Functional Motor Scale Expanded &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide24.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Ongoing SAPPHIRE Phase 3 Trial Overview&#160;&#160;24&#160;&#160;Randomized, double-blind,
              placebo-controlled, parallel arm design (n=204)&#160;&#160;Enrolling patients who are on SMN-directed therapy (nusinersen or risdiplam)&#160;&#160;Anticipate completing enrollment in 3Q 2023&#160;&#160;TREATMENT (52 weeks)&#160;&#160;Apitegromab (20 mg/kg IV q4w) + SMN-directed
              therapy&#160;&#160;Apitegromab (10 mg/kg IV q4w) + SMN-directed therapy&#160;&#160;Placebo (IV q4w) + SMN-directed therapy&#160;&#160;SCREENING&#160;&#160;MAIN POPULATION (n=156)&#160;&#160;Ages 2-12&#160;&#160;With nonambulatory Types 2 and 3 SMA&#160;&#160;N=52&#160;&#160;N=52&#160;&#160;N=52&#160;&#160;R&#160;&#160;Stratified to ensure balanced
              allocation across the three arms: &#160;&#160;Age at SMN therapy initiation(age &lt; 5 vs age &#8805; 5) &#160;&#160;SMN therapy (nusinersen vs. risdiplam)&#160;&#160;ENDPOINTS&#160;&#160;Primary Efficacy:&#160;&#160;Mean HFMSE change from baseline at 12 months &#160;&#160;Additional Efficacy
              Measures:&#160;&#160;RULM, WHO, other outcome measures &#160;&#160;Safety, PK/PD, ADA&#160;&#160;Additional Data Opportunities&#160;&#160;Exploratory population (age 13-21), in patients using SMN therapy&#160;&#160;Focused upon safety &amp; exploratory efficacy (n=48; 2:1 randomization
              between apitegromab 20 mg/kg vs placebo)&#160;&#160;Separate open-label extension study (after patients complete 12-month treatment period)&#160;&#160;Focused upon safety &amp; exploratory long-term efficacy&#160;&#160;ClinicalTrials.gov Identifier:
              NCT05156320&#160;&#160;HFMSE=Hammersmith Functional Motor Scale Expanded; RULM=Revised Upper Limb Module; R=randomization; SMA=spinal muscular atrophy; SMN=survival motor neuron.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide25.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Executing on the Promise: Apitegromab SMA Trials&#160;&#160;25&#160;&#160;SMA=Spinal Muscular
              Atrophy&#160;&#160;*Subject to regulatory approval &#160;&#160;WHERE WE AREPhase 3&#160;&#160;12-Month&#160;&#160;IN PROCESS&#160;&#160;Long-term&#160;&#160;EXTENSION&#160;&#160;3Q 2023 enrollment&#160;&#160;2024 data&#160;&#160;2025 launch* &#160;&#160;ANTICIPATED MILESTONES &#160;&#160;WHERE WE WERE Phase
              2&#160;&#160;12-Month&#160;&#160;COMPLETE&#160;&#160;24-Month&#160;&#160;EXTENSION&#160;&#160;COMPLETE&#160;&#160;36-Month&#160;&#160;EXTENSION&#160;&#160;COMPLETE &#160;&#160;WHERE WE PLAN TO GO&#160;&#160;Ambulatory patients&#160;&#160;Under 2 Years of Age (including those treated with gene therapy)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide26.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;26&#160;&#160;Potential first muscle-targeted therapy in SMA &#160;&#160;Robust body of data
              supports therapeutic potential &#160;&#160;Differentiation&#160;&#160;Strong pre-clinical evidence indicates upstream targeting of structurally differentiated latent myostatin avoids undesirable off-target effects &#160;&#160;Phase 2 TOPAZ trial demonstrated the
              therapeutic potential of inhibiting the latent forms of growth factors&#160;&#160;Strong&#160;&#160;Scientific&#160;&#160;Rationale&#160;&#160;TOPAZ has demonstrated sustained motor function gains to date in patients with nonambulatory Types 2 and 3 SMA &#160;&#160;Pivotal Phase 3 SAPPHIRE
              trial: enrollment completion expected in Q3 2023&#160;&#160;FDA has granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations&#160;&#160;European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan
              designations&#160;&#160;Clear&#160;&#160;Clinical&#160;&#160;Pathway&#160;&#160;SMN therapies prevent further degeneration of motor neurons but do not directly address muscle atrophy&#160;&#160;Apitegromab is a muscle-targeted approach and has the potential to address this unmet medical
              need&#160;&#160;Global SMA treatment market expected to grow in the next five years &#160;&#160;High Unmet&#160;&#160;Medical Need&#160;&#160;&amp; Significant&#160;&#160;Commercial Opportunity&#160;&#160;ApitegromabSummary&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide27.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181: Potential Transformative Backbone for a New Era ofCancer Immunotherapy&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide28.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Resistance to Checkpoint Inhibitor (CPI) Therapies Remains a Significant
              Clinical Challenge&#160;&#160;28&#160;&#160;1. Source: Gores, M. (2022).&#160;In the eye of the storm: PD-(L)1 inhibitors weathering turbulence [White paper].
              &#160;IQVIA.&#160;https://www.iqvia.com/library/white-papers/in-the-eye-of-the-storm-pd-l-1-inhibitors-weathering-turbulence &#160;&#160;2. Source: Carretero-Gonzalez et al. (2018) Oncotarget 9:8706-8715&#160;&#160;Meta-analysis of twelve randomized trials with control
              arm or adequate safety profile (includes nivolumab, pembrolizumab, and atezolizumab)&#160;&#160;Clinically derived rationale points to significant opportunity to increase checkpoint therapy responses by targeting TGF&#946;-1 &#160;&#160;7.9-10.41MILLION US patients
              on CPI therapies&#160;&#160;First-lineCPI therapy&#160;&#160;Second-line(or later) CPI therapy&#160;&#160;DID NOT respond &#160;&#160;63%&#160;&#160;2&#160;&#160;78%&#160;&#160;2&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide29.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Strong Scientific Rationale for the Role of TGF&#946; Inhibition in
              Immuno-Oncology&#160;&#160;29&#160;&#160;&#8220;Bristol Myers Squibb Enters Agreement to Acquire Forbius TGF-beta Program&#8221;&#160;&#160;August 2022.&#160;&#160;&#8220;Merck to Acquire Tilos Therapeutics: Merck Gains Portfolio of Investigational Antibodies Modulating TGF&#946;&#8221;&#160;&#160;$773 million total
              potential deal value&#160;&#160;June 2019.&#160;&#160;Selective inhibition of TGF&#946;-1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape&#160;&#160;Science Translational Medicine, March 25, 2020.&#160;&#160;Constance J. Martin,
              et al.&#160;&#160;Vol 12, Issue 536. DOI: 10.1126/scitranslmed.aay8456&#160;&#160;Nature (online), February 14, 2018.&#160;&#160;TGF&#946; attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells&#160;&#160;Sanjeev Mariathasan1*, Shannon J. Turley1*, Dorothee
              Nickles1*, Alessandra Castiglioni1, Kobe Yuen1, Yulei Wang1,&#160;&#160;Edward E. Kadel III1, Hartmut Koeppen1, Jillian L. Astarita1, Rafael Cubas1, Suchit Jhunjhunwala1, Romain Banchereau1,&#160;&#160;Yagai Yang1, Yinghui Guan1, Cecile Chalouni1, James Ziai1,
              Yasin &#350;enbabao&#287;lu1, Stephen Santoro1, Daniel Sheinson1, &#160;&#160;Jeffrey Hung1, Jennifer M. Giltnane1, Andrew A. Pierce1, Kathryn Mesh1, Steve Lianoglou1, Johannes Riegler1,&#160;&#160;Richard A. D. Carano1, Pontus Eriksson2, Mattias H&#246;glund2, Loan
              Somarriba3, Daniel L. Halligan3, Michiel S. van der Heijden4,&#160;&#160;Yohann Loriot5, Jonathan E. Rosenberg6, Lawrence Fong7, Ira Mellman1, Daniel S. Chen1, Marjorie Green1, Christina Derleth1,&#160;&#160;Gregg D. Fine1, Priti S. Hegde1, Richard Bourgon1
              &amp; Thomas Powles8&#160;&#160;Willy Hugo, Jesse M. Zaretsky, Lu Sun, Douglas B. Johnson, Antoni Ribas, Roger S. Lo&#160;&#160;Volume 165, Issue 1,&#160;24 March 2016, Pages 35-44&#160;&#160;Genomic and Transcriptomic Features of Response&#160;&#160;to Anti-PD-1 Therapy in Metastatic
              Melanoma&#160;&#160;July 24, 2020: https://doi.org/10.1038/ s41571-020-0403-1&#160;&#160;Nature Reviews , July 24, 2020&#160;&#160;NATURE REVIEWS | CLINICAL ONCOLOGY&#160;&#160;TGF&#946;: biology in cancer progression&#160;&#160;and immunotherapy&#160;&#160;Rik Derynck1,2,3, Shannon J. Turley4 and Rosemary
              J. Akhurst2,3&#160;&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide30.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181: Unique Latent TGF&#946;-1&#160;Selective Approach Designedto Overcome Checkpoint
              Inhibitor Resistance&#160;&#160;30&#160;&#160;Traditional Target&#8220;Mature&#8221; growth factor&#160;&#160;1. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats
              than active transforming growth factor beta 1, and a different tissue distribution. J Clin Invest. 1990 Dec;86(6):1976-84. doi: 10.1172/JCI114932. PMID: 2254455; PMCID: PMC329834.&#160;&#160;SRK-181: Latent TGF&#946;-1 Inhibitor&#160;&#160;Targets TGF&#946;-1&#160;&#160;Potential
              to overcome CPI resistance&#160;&#160;SRK-181 inhibits the TGF&#946;-1 implicated in check point inhibitor resistance&#160;&#160;Selective to &#946;-1 isoform&#160;&#160;Highly selective to &#946;-1 isoform vs. 2 and 3&#160;&#160;Increases therapeutic window and potentially avoids toxicities
              associated with non-selective TGF&#946; inhibition&#160;&#160;Other programs target multiple isoforms of TGF&#946;&#160;&#160;Context-independent&#160;&#160;Inhibits all sources of TGF&#946;-1&#160;&#160;SRK-181 targets all TGF&#946;-1 sources (LRRC33, GARP and LTBP1 and 3)&#160;&#160;Some programs only target
              one source&#160;&#160;Targets the latent form of TGF&#946;-1 &#160;&#160;Selectively targeting the latent form shuts off the growth factor before activation &#160;&#160;Increases opportunity to inhibit TGF&#946;-1&#160;&#160;Most other programs target the mature form of TGF&#946;-1&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide31.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181-mIgG1 + Anti-PD1 Overcomes Immune Exclusion&#160;&#160;31&#160;&#160;Anti-PD1/
              SRK-181-mIgG1&#160;&#160;Anti-PD1&#160;&#160;Overcoming immune exclusion&#160;&#160;Tumor micro-environment&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med. 2020 Mar 25;12(536):eaay8456.
              https://scholarrock.com/platform/publications.&#160;&#160;Data from MBT-2 syngeneic tumor model. Dose 10mg/kg QW for 4 weeks. &#160;&#160;Overcome Exclusion&#160;&#160;SRK-181-mIgG1 combination therapy led to influx and amplification of cytotoxic CD8+ cells in preclinical
              bladder tumor model&#160;&#160;Immune Exclusion&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide32.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;DRAGON Phase 1 POC Trial to Evaluate SRK-181&#8217;s Ability to Overcome Primary
              Resistance to Checkpoint Inhibitors&#160;&#160;32&#160;&#160;* A cohort of 2000 mg Q2W (n=3) was also evaluated.&#160;&#160;**The clear cell RCC and HNSCC cohorts will also explore the effects of SRK-181 in patients with relapsed response after anti-PD-1 treatment.&#160;&#160;1.
              NCT04291079 on www.clinicaltrials.gov.&#160;&#160;PART B&#160;&#160;SRK-181 + pembrolizumab;&#160;&#160;non-responders to prior anti-PD-1&#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Non-small cell lung cancer&#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Urothelial carcinoma&#160;&#160;SRK-181 +
              pembrolizumab&#160;&#160;Cutaneous melanoma&#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Clear cell renal cell carcinoma** &#160;&#160;SRK-181 + pembrolizumab&#160;&#160;Head and neck squamous cell** carcinoma&#160;&#160;COHORT&#160;&#160;TREATMENT&#160;&#160;PART A&#160;&#160;SRK-181 80 mg (n=1)&#160;&#160;SRK-181 240 mg (n=1)&#160;&#160;SRK-181
              800 mg (n=3)&#160;&#160;SRK-181 1600 mg (n=3)&#160;&#160;SRK-181 2400 mg (n=3)&#160;&#160;SRK-181 3000 mg (n=3)*&#160;&#160;SRK-181 &#160;&#160;all-comers&#160;&#160;A1&#160;&#160;A2&#160;&#160;SRK-181+anti-PD-(L)1; non-responders to prior anti-PD-(L)1&#160;&#160;SRK-181 240 mg (n=3)&#160;&#160;SRK-181 800 mg (n=3)&#160;&#160;SRK-181 1600 mg
              (n=3)&#160;&#160;SRK-181 2400 mg (n=3)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide33.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;DRAGON Part A: Safety &#160;&#160;PART A1 Monotherapy&#160;&#160;Treatment-Emergent AEs Related to
              SRK-181, All Grades &gt;10% &#160;&#160;PART A2 Combination Treatment&#160;&#160;Treatment-Emergent AEs Related to SRK-181 or Anti-PD(L)1, All Grades &gt;10%&#160;&#160;Dose
              (MG)&#160;&#160;80N=1&#160;&#160;240N=1&#160;&#160;800N=3&#160;&#160;1600N=4&#160;&#160;2400N=3&#160;&#160;3000N=3&#160;&#160;2000N=4&#160;&#160;AllN=19&#160;&#160;Fatigue&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;1&#160;&#160;3 (15.8%)&#160;&#160;Decreased Appetite&#160;&#160;1&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;2 (10.5%)&#160;&#160;Nausea&#160;&#160;1&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;1&#160;&#160;2 (10.5%)&#160;&#160;Dose (MG)&#160;&#160;240N=3&#160;&#160;800
              N=3&#160;&#160;1600N=6&#160;&#160;2400N=3&#160;&#160;AllN=15&#160;&#160;Rash maculo-papular&#160;&#160;1&#160;&#160;1&#160;&#160;1&#160;&#160;2&#160;&#160;5 (33.3%)&#160;&#160;Pruritus&#160;&#160;1&#160;&#160;1&#160;&#160;1&#160;&#160;1&#160;&#160;4 (26.7%)&#160;&#160;Rash&#160;&#160;0&#160;&#160;1&#160;&#160;0&#160;&#160;2&#160;&#160;3 (20.0%)&#160;&#160;Diarrhea&#160;&#160;0&#160;&#160;0&#160;&#160;2&#160;&#160;0&#160;&#160;2 (13.3%)&#160;&#160;Pemphigoid&#160;&#160;0&#160;&#160;0&#160;&#160;0&#160;&#160;2&#160;&#160;2 (13.3%)&#160;&#160;All dose levels were administered
              q3w except 2000 mg, which was administered q2w.&#160;&#160;Treatment-related Grade 3 AEs:&#160;&#160;Alanine aminotransferase increased (1 patient)&#160;&#160;Treatment-related SAEs:&#160;&#160;None&#160;&#160;No DLTs&#160;&#160;were observed up to 3000 mg q3w and 2000 mg q2w&#160;&#160;No Grade 4 or 5
              treatment-related AEs occurred&#160;&#160;Treatment-related Grade 3 AEs:&#160;&#160;Pruritus (2 patients), blister, immune-mediated lung disease, pemphigoid, rash, rash maculo-popular and rash vesicular (1 patient each)&#160;&#160;Treatment-related SAEs:&#160;&#160;Blister,
              pruritus, and rash (all in 1 patient) and immune-mediated lung disease (1 patient)&#160;&#160;No DLTs&#160;&#160;were observed up to 2400 mg q3w&#160;&#160;No Grade 4 or 5 treatment-related AEs occurred&#160;&#160;Yap T et al. Safety and Efficacy Results of SRK-181, a latent TGF&#946;1
              inhibitor, from a Phase 1 trial (DRAGON Trial); Presented at ESMO-TAT; March 7, 2023. *Clinical cutoff date: December 2, 2022. Response is assessed using RECIST v1.1 by PI; the scan is performed during screening, 6 weeks after first dose,
              every 9 weeks for the next 6 months of treatment, and every 12 weeks thereafter. SRK-181 is an investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not been approved by the US FDA or any other health
              authority, and its safety and efficacy have not been established.&#160;&#160;33&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide34.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Duration of Treatment&#160;&#160;DRAGON Part A: Preliminary Efficacy Data*&#160;&#160;34&#160;&#160;Part A1
              (n=19)&#160;&#160;Part A2 (n=15)&#160;&#160;8 patients had a best response of stable disease (SD) &#160;&#160;All 3 patients with ovarian cancer were stable for 6-10 months&#160;&#160;Yap T et al. Safety and Efficacy Results of SRK-181, a latent TGF&#946;1 inhibitor, from a Phase 1
              trial (DRAGON Trial); Presented at ESMO-TAT; March 7, 2023. *Clinical cutoff date: December 2, 2022. Response is assessed using RECIST v1.1 by PI; the scan is performed during screening, 6 weeks after first dose, every 9 weeks for the next 6
              months of treatment, and every 12 weeks thereafter. SRK-181 is an investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not been approved by the US FDA or any other health authority, and its safety
              and efficacy have not been established.&#160;&#160;At 800 mg q3w, 1 partial response (PR) was observed in patient with anti-PD-1-resistant clear cell renal cell carcinoma (ccRCC)&#160;&#160;9 patients had best response of SD&#160;&#160;6 patients (green highlight) were
              stable beyond the 16-week cutoff &#160;&#160;1 ongoing patient with head and neck cancer had a 29.4% tumor reduction &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide35.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Preliminary Efficacy Data in Combination with Pembrolizumab: Best Response in
              Target Lesions&#160;&#160;35&#160;&#160;Best Response in Target Lesions&#160;&#160;Best Response of PR&#160;&#160;Best Response of SD&#160;&#160;Best Response of PD&#160;&#160;Ongoing&#160;&#160;Percent Change from Baseline&#160;&#160;800 mg q3w&#160;&#160;800 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;1600 mg q3w&#160;&#160;2400 mg
              q3w&#160;&#160;2400 mg q3w&#160;&#160;2400 mg q3w&#160;&#160;240 mg q3w&#160;&#160;240 mg q3w&#160;&#160;800 mg q3w&#160;&#160;Head and Neck&#160;&#160;Head and Neck&#160;&#160;Head and Neck&#160;&#160;Uveal Melanoma&#160;&#160;NSCLC&#160;&#160;Melanoma&#160;&#160;Melanoma&#160;&#160;Liver&#160;&#160;RCC&#160;&#160;RCC&#160;&#160;TNBC&#160;&#160;Squamous Cell Skin Carcinoma&#160;&#160;Part A2&#160;&#160;Yap T et al. Safety and
              Efficacy Results of SRK-181, a latent TGF&#946;1 inhibitor, from a Phase 1 trial (DRAGON Trial); Presented at ESMO-TAT; March 7, 2023. *Clinical cutoff date: December 2, 2022. Response is assessed using RECIST v1.1 by PI; the scan is performed
              during screening, 6 weeks after first dose, every 9 weeks for the next 6 months of treatment, and every 12 weeks thereafter. SRK-181 is an investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not
              been approved by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Part B (as of 12/2/22)&#160;&#160;20 patients dosed across multiple cohorts&#160;&#160;Two confirmed PRs ongoing patients with anti-PD-1 resistant
              clear cell renal cell carcinoma &#160;&#160;All dose levels were generally well tolerated SRK-181 dose of 1500 mg q3w or 1000 mg q2w in combination with anti&#8209;PD-(L)1 for Part B &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide36.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;36&#160;&#160;Summary of ccRCC Patients on Combination Treatment &#160;&#160;(Part A2&#160;and Part
              B)&#160;&#160;11 ccRCC patients enrolled&#160;&#160;n=2 in Part A2 (all discontinued from study) and n=9 in Part B (5 pts remain on study)&#160;&#160;enrollment in Part B continues&#160;&#160;3 confirmed PRs observed&#160;in ccRCC patients&#160;&#160;Patients are anti-PD-1 resistant patient (no
              response on prior anti-PD-1 therapy and disease progress on the most recent prior anti-PD-1 therapy) &#160;&#160;ORR: 27% (3/11)&#160;&#160;Yap T et al. Safety and Efficacy Results of SRK-181, a latent TGF&#946;1 inhibitor, from a Phase 1 trial (DRAGON Trial);
              Presented at ESMO-TAT; March 7, 2023. *Clinical cutoff date: December 2, 2022. Response is assessed by investiogator using RECIST v1.1 by PI; the scan is performed during screening, 6 weeks after first dose, every 9 weeks for the next 6
              months of treatment, and every 12 weeks thereafter. SRK-181 is an investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not been approved by the US FDA or any other health authority, and its safety
              and efficacy have not been established.&#160;&#160;As of clinical cutoff date of Dec 2, 2022 &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide37.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Summary of ccRCC Patients with PR in Dragon (Part A2 and Part B,
              Combination&#160;Treatment)&#160;&#160;Responded Pts&#160;&#160;SRK-181 Dose &#160;&#160;(mg, Q3W)&#160;&#160;Age (Year)/&#160;&#160; Gender&#160;&#160;Lines of &#160;&#160;Prior Therapy&#160;&#160;IMDC Score &#160;&#160;at Screening&#160;&#160;Metastatic Sites &#160;&#160;at Screening&#160;&#160;Pt Status&#160;&#160;Duration of &#160;&#160;Treatment (wks)&#160;&#160;Best % Change in &#160;&#160;SOD*
              from Baseline&#160;&#160;Pt #1&#160;&#160;Part A2, 800 &#160;&#160;56/M&#160;&#160;Sunitinib&#160;&#160;Nivolumab/Ipilimumab&#160;&#160;Cabozantinib&#160;&#160;Lenvatinib/Everolimus&#160;&#160;Pembrolizumab/Axitinib&#160;&#160;3 &#160;&#160;(Poor risk)&#160;&#160;Lung/ Lymph Nodes/ &#160;&#160;Pleural/ Pancreas/ Bone&#160;&#160;Off study&#160;&#160;30&#160;&#160;-57%&#160;&#160;Pt #2&#160;&#160;Part B,
              1500&#160;&#160;58/M&#160;&#160;Nivolumab/Ipilimumab&#160;&#160;Cabozantinib&#160;&#160;3 &#160;&#160;(Poor risk)&#160;&#160;Lung/ Lymph Nodes/Liver&#160;&#160;Ongoing&#160;&#160;32+&#160;&#160;(by Dec 2, 2022)&#160;&#160;-67%&#160;&#160;Pt #3&#160;&#160;Part B, 1500&#160;&#160;63/M&#160;&#160;Nivolumab/Ipilimumab&#160;&#160;Nivolumab&#160;&#160;Cabozantinib&#160;&#160;2 &#160;&#160;(Intermediate &#160;&#160;risk)&#160;&#160;Lung/ Lymph
              Nodes&#160;&#160;Ongoing&#160;&#160;16+&#160;&#160;(by Dec 2, 2022)&#160;&#160;-50%&#160;&#160;Pt#2: Screening&#160;&#160;Common hepatic lymph node&#160;&#160;4.0 &#215; 3.0 (cm)&#160;&#160;Pt#2: C7D8 &#160;&#160;Common hepatic lymph node&#160;&#160;3.2 &#215; 1.7 (cm)&#160;&#160;Pt#1: Screening&#160;&#160;Liver nodule segment II&#160;&#160;1.7 &#215; 1.4 (cm)&#160;&#160;Pt#1: C8D1 &#160;&#160;Liver
              nodule segment II&#160;&#160;0.0 &#215; 0.0 (cm)&#160;&#160;Yap T et al. Safety and Efficacy Results of SRK-181, a latent TGF&#946;1 inhibitor, from a Phase 1 trial (DRAGON Trial); Presented at ESMO-TAT; March 7, 2023. *Clinical cutoff date: December 2, 2022. Response is
              assessed using RECIST v1.1 by PI; the scan is performed during screening, 6 weeks after first dose, every 9 weeks for the next 6 months of treatment, and every 12 weeks thereafter. *SOD: sum of diameters in target lesions. SRK-181 is an
              investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not been approved by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;37&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide38.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181: Encouraging Early Clinical Data Consistent with Hypothesis &#160;&#160;38&#160;&#160;TGF&#946;
              pathway evaluation (PD)&#160;&#160;Target engagement (blood)&#160;&#160;TGF&#946;-1 signaling (tumor p-SMAD2 &amp; RNAseq)&#160;&#160;Immunophenotyping, including immune exclusion status&#160;&#160;Tumor immune contexture (e.g., tumor CD8+ T cells)&#160;&#160;Immune cell contexture (tumor &amp;
              blood MDSCs)&#160;&#160;Immune response markers (e.g., IO gene signature) &#160;&#160;Therapeutically relevant dose&#160;&#160;Drug exposure needed for efficacy&#160;&#160;Objective response&#160;&#160;Anti-tumor response and survival benefits&#160;&#160;TGF&#946; pathway evaluation (PD)&#160;&#160;Target engagement
              (blood)&#160;&#160;TGF&#946;-1 signaling (tumor p-SMAD2 &amp; RNAseq)&#160;&#160;Immunophenotyping, including immune exclusion status&#160;&#160;Tumor immune contexture (e.g., tumor CD8+ T cells)&#160;&#160;Immune cell contexture (tumor &amp; blood MDSC&#8217;s)&#160;&#160;Immune response markers
              (e.g., IO gene signature)&#160;&#160;Therapeutically relevant dose&#160;&#160;Dosing regimens achieved target steady state levels&#160;&#160;Objective response&#160;&#160;Anti-tumor response observed (partial responses)&#160;&#160;Preclinical Data&#160;&#160;Phase 1 DRAGON proof-of-concept trial&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide39.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;39&#160;&#160;*(PD-1/PD-L1)&#160;&#160;First in class monoclonal antibody targeting latent and
              context-independent binding to TGF&#946;1&#160;&#160;Differentiated from other TGF&#946; inhibitors by its novel selectivity&#160;&#160;Offers potential to avoid toxicity and dose-limiting challenges of non-selective TGF&#946; inhibition approaches&#160;&#160;Differentiation&#160;&#160;Emerging
              evidence implicates TGF&#946;1 as driving resistance to checkpoint inhibitor therapies&#160;&#160;Potent and selective inhibitor of latent TGF&#946;1 activation in preclinical studies&#160;&#160;Strong safety and preclinical efficacy
              data&#160;&#160;Strong&#160;&#160;Scientific&#160;&#160;Rationale&#160;&#160;DRAGON Part A demonstrated ability to escalate to high doses of SRK-181 at levels exceeding the anticipated efficacious drug exposure level&#160;&#160;Advanced to DRAGON Part B: Evaluating SRK-181 in 5 parallel
              tumor-specific cohorts, with efficient path towards early POC for each&#160;&#160;Early efficacy signals have been observed&#160;&#160;Clear&#160;&#160;Clinical&#160;&#160;Pathway&#160;&#160;PD-(L)1* becoming a standard of care therapy in many tumor types; the market for synergistic
              combination product would be vast&#160;&#160;SRK-181 could potentially be used in many tumor types, potentially both in patients resistant to PD-(L)1 and in CPI na&#239;ve patients, as well as other therapeutic applications&#160;&#160;High Unmet&#160;&#160;Medical Need&#160;&#160;&amp;
              Large&#160;&#160;Commercial Opportunity&#160;&#160;SRK-181Summary&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide40.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Next Horizon: Fibrosis&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide41.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TGF&#946; is Established as Key Driver of Fibrosis Across Multiple Diseases
              &#160;&#160;41&#160;&#160;Nature Reviews , April 25, 2016&#160;&#160;NATURE REVIEWS | NEPHROLOGY&#160;&#160;TGF-&#946;: the master regulator of fibrosis&#160;&#160;Xiao-ming Meng1, David J. Nikolic-Paterson2 and Hui Yao Lan3&#160;&#160;Nature Reviews. August 19, 2014&#160;&#160;NATURE REVIEWS |
              RHEUMATOLOGY&#160;&#160;Transforming growth factor &#946;&#8213;at the centre&#160;&#160;of systemic sclerosis&#160;&#160;Robert Lafyatis&#160;&#160;Int. J. Mol. Sci. August 27, 2018&#160;&#160;Targeting TGF-&#946; Signaling in Kidney Fibrosis&#160;&#160;Yoshitaka Isaka&#160;&#160;J. Am. Soc. Nephrol. December 3,
              2017&#160;&#160;Targeting Anti-TGF-&#946; Therapy to Fibrotic Kidneys&#160;&#160;with a Dual Specificity Antibody Approach&#160;&#160;Steve McGaraughty,* Rachel A. Davis-Taber,&#8224; Chang Z. Zhu,* Todd B. Cole,*&#160;&#160;Arthur L. Nikkel,* Meha Chhaya,&#8224; Kelly J. Doyle,* Lauren M. Olson,*
              Gregory M. Preston,&#8224;&#160;&#160;Chrisine M. Grinnell,&#8224; Katherine M. Salte,* Anthony M. Giamis,* Yanping Luo,*&#160;&#160;Victor Sun,&#8224; Andrew D. Goodearl,&#8224; Murali Gopalakrishnan,* and Susan E. Lacy&#8224;&#160;&#160;J Pathol, July 25, 2021&#160;&#160;TGF-&#946; as a driver of fibrosis:
              physiological roles and therapeutic opportunities&#160;&#160;Erine H Budi1,&#160;Johanna R Schaub1,&#160;Martin Decaris1,&#160;Scott Turner1,&#160;Rik Derynck2&#160;&#160;J Receptors Sign Trans, Feb 13, 2020&#160;&#160;Inevitable role of TGF-&#946; in progression of nonalcoholic fatty liver
              disease&#160;&#160;Bhagyalakshmi Nair and Lekshmi R. Nath&#160;&#160;PNAS, February 24, 1986&#160;&#160;Transforming growth factor type &#946;: Rapid induction of fibrosis and&#160;&#160;angiogenesis in vivo and stimulation of collagen formation in vitro&#160;&#160;ANITA B. ROBERTS* MICHAEL B.
              SPORN*, RICHARD K. ASSOIAN*, JOSEPH M. SMITH*, NANETTE S. ROCHE*, LALAGE M. WAKEFIELD*, URSULA I. HEINE*, LANCE A. LIOTTA*, VINCENT FALANGA&#8224;, JOHN H. KEHRL&#8225;, AND ANTHONY S. FAUCI&#8225;&#160;&#160;Proc Am Thorac Soc, July 3, 2006&#160;&#160;Transforming Growth Factor
              &#946;&#160;&#160;A Central Modulator of Pulmonary and Airway Inflammation and Fibrosis&#160;&#160;Dean Sheppard&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide42.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;GARP Presents TGF&#946; on Tregs&#160;&#160;LRRC33 Presents TGF&#946; on Macrophages&#160;&#160;LTBP1 &amp; 3
              Present TGF&#946; in Connective Tissue&#160;&#160;Targeting Presenting Molecule/TGF&#946;-1 Complexes Provides Context Specificity &#160;&#160;Targeting Latent TGF&#946;-1 Complexes Creates Multiple &#8220;Handles&#8221; For Selectivity&#160;&#160;42&#160;&#160;Latent TGF-&#946;&#160;&#160;GARP&#160;&#160;Treg&#160;&#160;Integrin expressing
              cell&#160;&#160;avb8&#160;&#160;Integrin&#160;&#160;Latent TGF-&#946;&#160;&#160;LRRC33&#160;&#160;Macrophage&#160;&#160;Integrin expressing cell&#160;&#160;avb8&#160;&#160;Integrin&#160;&#160;Latent TGF-&#946; &#160;&#160;binding protein&#160;&#160; (LTBP)&#160;&#160;Extracellular matrix&#160;&#160;Fibrillin&#160;&#160;Latent TGF-&#946;&#160;&#160;Epithelial&#160;&#160;Cell&#160;&#160;avb6&#160;&#160;Integrin&#160;&#160;Latent TGF&#946;-1&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide43.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;LTBP-49247 Reduced TGF&#946;&#160;Signaling and Fibrosis in Preclinical Models of&#160;Kidney
              Fibrosis&#160;&#160;43&#160;&#160;LTBP-49247 reduced a TGF&#946; PD biomarker in kidneys of&#160;Col4a3 KO mice (Alport Syndrome model)&#160;&#160;LTBP-49247 reduced fibrosis in&#160;kidneys of Alport model&#160;&#160;** p &lt; 0.01&#160;&#160;One way ANOVA vs. IgG&#160;&#160;HYP=hydroxyproline&#160;&#160;Efficacy also seen
              in rat model of kidney fibrosis &#160;&#160;No observed toxicity in mouse 13-week non-GLP repeat dose study&#160;&#160;Favorable PK in cynomolgus monkeys (t1/2 ~28 days) suggests LTBP-49247 is amenable to clinical subcutaneous dosing with promising
              developability profile&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide44.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Significant Opportunities to Address High Unmet Need Across Multiple Fibrotic
              Indications&#160;&#160;44&#160;&#160;Alport Syndrome (AS) &#160;&#160;Focal Segmental Glomerulosclerosis (FSGS) &#160;&#160;IgA Nephropathy (IgAN)&#160;&#160;Primary Sclerosing Cholangitis (PSC)&#160;&#160;Diffuse Cutaneous Systemic Sclerosis (dcSSc)&#160;&#160;Idiopathic Pulmonary Fibrosis (IPF)&#160;&#160;Collectively,
              significant commercial potential given large patient population with clear high unmet need given poor outcomes and lack of effective therapeutics&#160;&#160;Significant impact to delay or stop progression to end-stage disease and organ transplant
              &#160;&#160;Expansion opportunities via other indications given shared etiologies&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide45.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Next Horizon: Iron-Restricted Anemia&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide46.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;BMP6/RGMc Pathway is a Well Validated Regulator of Systemic Iron Homeostasis
              &#160;&#160;46&#160;&#160;Fig: Muckenthaler, M.U., Rivella, S., Hentze, M.W. and Galy, B. (2017) A Red Carpet for Iron Metaboism. Cell, 168(3): 344-361&#160;&#160;1: Kuns-Hashimoto R, et al. (2008) Selective binding of RGMc/hemojuvelin, a key protein in systemic iron
              metabolism, to BMP-2 and neogenin. Am J Physiol Cell Physiol 294(4):C994-C1003&#160;&#160;2: Constante M, et al.. (2007) Repression of repulsive guidance molecule C during inflammation is independent of Hfe and involves tumor necrosis factor-alpha. Am
              J Pathol 170(2):497-504&#160;&#160;3: Core A.B., et al. (2014) Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front Pharmacol. 5:104. &#160;&#160;4. Wang CY and Babitt JL. (2016) Hepcidin Regulation in the Anemia of Inflammation.
              Curr Opin Hematol 23(3): 189-197.&#160;&#160;Elevation of proinflammatory cytokines drives increased hepcidin expression and results in anemia due to functional iron deficiency4&#160;&#160;Anemia of Inflammation/ Chronic Disease&#160;&#160;Hepcidin&#160;&#160;Serum
              iron&#160;&#160;Untreated&#160;&#160;Hepcidin&#160;&#160;Serum iron&#160;&#160;Ab treated&#160;&#160;Human mutations in HJV/RGMc establish it as a central player in hepcidin regulation1&#160;&#160;Knockout phenotypes and tissue-specific expression pattern demonstrate that its predominant role is in
              iron homeostasis2&#160;&#160;Member of repulsive guidance molecule (RGM) family (RGMa, RGMb, RGMc/HJV) that act as BMP co-receptors to modulate BMP signaling3&#160;&#160;HJV/RGMc is a key player in the regulation of hepcidin expression&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide47.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;HJV-35202: An Investigational High-Affinity Antibody Demonstrating Selective
              Inhibition of HJV/RGMc and Robust PK/PD in Cynos&#160;&#160;47&#160;&#160;Potent in vitro binding affinity (KD=3.9E-11)&#160;&#160;Highly specific to RGMc/HJV with well understood mechanism&#160;&#160;Sustained PD effect in single dose Cyno study&#160;&#160;Specific to RGMc over other RGM
              family members&#160;&#160;Nicholls S.B., et al. Poster: RGMc-selective antibodies modulate iron homeostasis in vivo, 12th International BMP Conference, Tokyo, October 2018&#160;&#160;Scholar Rock, Data on File&#160;&#160;High-affinity antibody&#160;&#160;Specific to RGMc, with
              mechanism of specificity understood&#160;&#160;Cross-reactive to human, mouse, rat and cyno&#160;&#160;Sustained PD observed in healthy rats and cynos, with clear PK/PD relationship&#160;&#160;Highly manufacturable framework with no sequence liabilities&#160;&#160;Formulatable into
              a subcutaneous format (150 mg/mL)&#160;&#160;HJV-35202 (mg/mL)&#160;&#160;Serum Iron and UIBC (mg/dL) &#160;&#160;PK: HJV-35202 (10mg/kg, IV)&#160;&#160;PD: UIBC: HJV-35202 (10mg/kg, IV)&#160;&#160;PDF: Serum Iron: HJV-35202 (10mg/kg, IV)&#160;&#160;Octet Response
              Units&#160;&#160;RGMa&#160;&#160;RGMb&#160;&#160;RGMc/HJV&#160;&#160;RGMa&#160;&#160;RGMb&#160;&#160;RGMc/HJV&#160;&#160;Key Attributes of HJV-35202:1,2&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide48.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Significant Opportunities to Target Iron-Restricted Anemias Across Multiple
              Indications&#160;&#160;48&#160;&#160;Chronic Kidney Disease (CKD)&#160;&#160;Anemia of Chronic Inflammation (AI)&#160;&#160;Myelofibrosis (MF)&#160;&#160;Targeting RGMc/HJV for anemia is well validated and relatively de-risked&#160;&#160;High levels of hepcidin, the main regulator of systemic iron
              metabolism, are associated with anemia across various diseases&#160;&#160;Safe and convenient RGMc inhibitor has promise of improving patient outcomes across multiple indications as stand alone or in combination with SoC &#160;&#160;Significant and clear unmet
              need given lack of approved treatments or severe limitations of current treatments&#160;&#160;Well defined patient population&#160;&#160;Collectively, sizeable commercial opportunity given relatively large population&#160;&#160;Potential for rapid POC with clear
              regulatory path&#160;&#160;Opportunity to build an anemia franchise with initial POC and indication expansion in the future&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide49.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Scholar Rock Summary &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide50.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;50&#160;&#160;Key Investment Highlights&#160;&#160;Revolutionary Platform&#160;&#160;Overcome the
              Challenges&#160;&#160;targeting the latent forms of growth factors&#160;&#160;Discover and Develop&#160;&#160;monoclonal antibodies with extraordinary selectivity&#160;&#160;Positioned For Success&#160;&#160;Upcoming Data Readouts&#160;&#160;for both clinical programs&#160;&#160;$205M financing in June
              2022&#160;&#160;Cash balance of $275M as of March 31, 2023; anticipated runway into 2025&#160;&#160;Robust Clinical Pipeline&#160;&#160;SRK-181 (Phase 1)&#160;&#160;Potential to shift current treatment landscape for cancer patients with CPI resistance&#160;&#160;Apitegromab (Phase
              3)&#160;&#160;Potential first-in-class&#160;&#160;Significant market opportunity &#160;&#160;Program on track&#160;&#160;Clear path to approval&#160;&#160;Discovery-stage Pipeline&#160;&#160;Fibrosis and iron-restricted anemia&#160;&#160;Strategic optionality &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide51.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Appendix&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide52.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ Baseline Characteristics1,2&#160;&#160;52&#160;&#160;*Patients on average received ~2 years of
              nusinersen treatment at baseline and ~3 years of nusinersen treatment by the end of the TOPAZ study (12-months). SMN2 copy numbers were not available for all patients. &#8224;12-month baseline characteristics recorded in the table, 1-cohort 1
              patient and 1- cohort 2 patient discontinued during 24M Extension Period A. All discontinuations were&#160;for reasons unrelated to study drug.&#160;&#160;HFMSE, Hammersmith Functional Motor Scale&#8211;Expanded; max, maximum; min, minimum; RHS, Revised
              Hammersmith Scale; SMN, survival motor neuron.&#160;&#160;1. Crawford T, et al. Neuromuscul Disord. 2022;32(Suppl1):S86-S87. P102. 2. Crawford T, et al. TOPAZ Extension: 24-month Efficacy and Safety of Apitegromab in Patients With Later-onset Spinal
              Muscular Atrophy (Type 2 and Type 3 SMA). Presented at CureSMA Annual Conference; June 16-19, 2022.&#160;&#160;N&#160;(dosed)&#160;&#160;Mean age (min, max)&#160;&#160;Mean RHS (min, max)&#160;&#160;Mean HFMSE (min, max)&#160;&#160;Prior Nusinersen, Months&#160;&#160;Mean (min, max)*&#160;&#160;No. of patients
              with&#160;&#160;2,3, or 4 SMN2 copies&#160;&#160;Discontinuation(s)&#160;&#160;Ambulatory&#160;&#160;COHORT 1: Age 5-21&#160;&#160;20 mg/kg&#160;&#160;monotherapy&#160;&#160;11&#160;&#160;12&#160; (7, 19)&#160;&#160;48&#160; (26, 63)&#160;&#160;&#160;&#160;&#160;N/A&#160;&#160;1, 4, 4&#160;&#160;0&#160;&#160;20 mg/kg&#160;&#160;+ nusinersen&#160;&#160;12&#160;&#160;13&#160; (7, 21)&#160;&#160;51&#160; (43, 62)&#160;&#160;20&#160;(12, 28)&#160;&#160;0, 9,
              1&#160;&#160;1&#8224;&#160;&#160;Pooled&#160;&#160;23&#160;&#160;13&#160; (7, 21)&#160;&#160;50&#160; (26, 63)&#160;&#160;N/A&#160;&#160;1, 13, 5&#160;&#160;1&#8224;&#160;&#160;Nonambulatory&#160;&#160;COHORT 2: Age 5-21&#160;&#160;20 mg/kg&#160;&#160;+ nusinersen&#160;&#160;15&#160;&#160;12&#160; (8, 19)&#160;&#160;&#160;&#160;&#160;23&#160; (13, 39)&#160;&#160;25 (12, 39)&#160;&#160;0, 11, 2&#160;&#160;0&#160;&#160;COHORT 3: Age 2+&#160;&#160;20 mg/kg&#160;&#160;+ nusinersen&#160;&#160;10&#160;&#160;4&#160; (2,
              6)&#160;&#160;&#160;&#160;&#160;24&#160; (14, 42)&#160;&#160;24 (10, 34)&#160;&#160;1, 8, 0&#160;&#160;0&#160;&#160;2 mg/kg&#160;&#160;+ nusinersen&#160;&#160;10&#160;&#160;4&#160; (2, 6)&#160;&#160;26&#160; (12, 44)&#160;&#160;1, 8, 1&#160;&#160;0&#160;&#160;Pooled&#160;&#160;20&#160;&#160;4&#160; (2, 6)&#160;&#160;25&#160; (12, 44)&#160;&#160;2, 16, 1&#160;&#160;0&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide53.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ Patient Disposition Over 36 Months&#160;&#160;a. Patients stratified based on
              previous treatment with approved SMN therapy.&#160;&#160;b. Patients randomized to receive 2 or 20 mg/kg apitegromab.&#160;&#160;*Includes patients who crossed over from 2 mg/kg to 20mg/kg starting week 68 through week 104&#160;&#160;** Excludes patients on
              monotherapy&#160;&#160;SMN Rx=SMN therapy.&#160;&#160;SMN Rx &#8805; 5&#160;&#160;ENROLLMENT n=58 &#160;&#160;YEAR 1: Thx Period n=57&#160;&#160;YEARS 2-4: ExtensionN=50&#160;&#160;ONYX&#160;&#160;Study&#160;&#160;NONAMBULATORY&#160;&#160;N=20&#160;&#160;Ages &#8805; 2&#160;&#160;Type 2 SMA&#160;&#160;&#160;n=20&#160;&#160;Apitegromab 20 mg + nusinersen*&#160;&#160;SMN
              Therapy&#160;&#160;Yes&#160;&#160;No&#160;&#160;n=10&#160;&#160;n=10&#160;&#160;Apitegromab 2 mg + nusinersen&#160;&#160;Apitegromab 20 mg + nusinersen&#160;&#160;NONAMBULATORY&#160;&#160;N=15&#160;&#160;Ages 5-21&#160;&#160;Type 2 or Type 3 SMA&#160;&#160;n=15&#160;&#160;Apitegromab 20 mg + nusinersen&#160;&#160;n=15&#160;&#160;Apitegromab 20 mg + nusinersen&#160;&#160;1 withdrew consent
              (COVID concern)&#160;&#160;57 ENROLLED&#160;&#160;7 discontinued &#160;&#160;2 due to concerns with COVID-19&#160;&#160;5 on monotherapy due to lack of benefit&#160;&#160;&gt;90% of patients on combination therapy remained in study**&#160;&#160;TOPAZ patient retention&#160;&#160;PRIMARY
              TREATMENT:&#160;&#160;EXTENSION:&#160;&#160;58 ENROLLED&#160;&#160;57 completed primary treatment period and enrolled in the extension study &#160;&#160;1 withdrew consent due to fatigue &amp; weight gain&#160;&#160;SMN Therapy&#160;&#160;AMBULATORY &#160;&#160;N=23&#160;&#160;Ages 5-21&#160;&#160;Type 3 SMA&#160;&#160;1 withdrew consent
              (fatigue /weight gain)&#160;&#160;1 withdrew consent (COVID concern)&#160;&#160;Yes&#160;&#160;No&#160;&#160;n=11&#160;&#160;n=12&#160;&#160;Apitegromab 20 mg monotherapy&#160;&#160;Apitegromab 20 mg + nusinersen&#160;&#160;n=11&#160;&#160;n=11&#160;&#160;Apitegromab 20 mg monotherapy&#160;&#160;Apitegromab 20 mg + nusinersen&#160;&#160;4 withdrew consent
              (lack of benefit)&#160;&#160;1 withdrew consent (lack of benefit)&#160;&#160;53&#160;&#160;SMN Rx &lt; 5&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide54.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Time (weeks)&#160;&#160;No. of observations&#160;&#160;Year 3&#160;&#160;Year 2&#160;&#160;Year 1&#160;&#160;Year 3&#160;&#160;Year 2&#160;&#160;Year
              1&#160;&#160;PROMIS Fatigue (Proxy)&#160;&#160;Year 2&#160;&#160;Year 3&#160;&#160;Year 1&#160;&#160;Year 2&#160;&#160;Year 3&#160;&#160;Year 1&#160;&#160;Pooled Nonambulatory Patients | Age 2 &#8211; 12 | All Doses | Over 36 MonthsImprovements in PRO Measures Consistent With Motor Function&#160;&#160;54&#160;&#160;Time (weeks)&#160;&#160;No. of
              observations&#160;&#160;IMPROVEMENT&#160;&#160;PEDI-CAT Daily Activities&#160;&#160;IMPROVEMENT&#160;&#160;IMPROVEMENT&#160;&#160; N = 29.; Baseline mean age=5.5 |Time on SMN Rx=24.6m &#160;&#160;HFMSE&#160;&#160;29&#160;&#160;29&#160;&#160;29&#160;&#160;23&#160;&#160;24&#160;&#160;26&#160;&#160;26&#160;&#160;26&#160;&#160;26&#160;&#160;23&#160;&#160;22&#160;&#160;23&#160;&#160;22&#160;&#160;Change from baseline
              (&#177;SE)&#160;&#160;25&#160;&#160;23&#160;&#160;24&#160;&#160;16&#160;&#160;18&#160;&#160;20&#160;&#160;20&#160;&#160;18&#160;&#160;23&#160;&#160;19&#160;&#160;14&#160;&#160;15&#160;&#160;13&#160;&#160;IMPROVEMENT&#160;&#160;RULM&#160;&#160;28&#160;&#160;28&#160;&#160;28&#160;&#160;22&#160;&#160;23&#160;&#160;26&#160;&#160;25&#160;&#160;26&#160;&#160;26&#160;&#160;25&#160;&#160;22&#160;&#160;22&#160;&#160;22&#160;&#160;Change from baseline (&#177;SE)&#160;&#160;21&#160;&#160;19&#160;&#160;18&#160;&#160;15&#160;&#160;15&#160;&#160;18&#160;&#160;12&#160;&#160;17&#160;&#160;16&#160;&#160;16&#160;&#160;13&#160;&#160;12&#160;&#160;11&#160;&#160;HFMSE=Hammersmith Functional
              Motor Scale Expanded; OC=observed case; PEDI-CAT=Pediatric Evaluation of Disability Inventory Computer Adaptive Test; PROMIS=Patient Reported Outcome Measurement Information System; RULM=Revised upper limb module; SE=standard error of the
              mean. SMN Rx=SMN therapy. Data on File. Scholar Rock, Inc. Cambridge, MA. Data cutoff date as of March 13, 2023. Error bars represent standard error (SE). Data cutoff date as of March 13, 2023. The updated PEDI-CAT analysis included
              additional records (2 at 12 months and 1 at 24 months) that were not available at the time of previous analysis. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has
              not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide55.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;PEDI-CAT Daily Activities Over 36 Months Improvements Were Substantial and
              Sustained&#160;&#160;55&#160;&#160;For the 36-month evaluation, an observed case analysis was conducted, which pooled all the nonambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis population included
              patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). Error bars represent SE. CI represents confidence interval. SMN Rx=SMN
              therapy. Data cutoff date as of March 13, 2023. The updated analysis included additional records (2 at 12 months and 1 at 24 months) that were not available at the time of previous analysis. Apitegromab is an investigational drug candidate
              being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Baseline mean age=7.3 |&#8202;Time on
              SMN Rx=24.1m &#160;&#160;Baseline mean age=5.5 |&#8202;Time on SMN Rx=24.6m &#160;&#160;n=&#160;&#160;35&#160;&#160;21&#160;&#160;25&#160;&#160;23&#160;&#160;17&#160;&#160;95% CI=&#160;&#160;(-0.0,&#8201;2.6)&#160;&#160;(-0.1,&#8201;2.6)&#160;&#160;(0.9,&#8201;3.5)&#160;&#160;(-0.1,&#8201;4.5)&#160;&#160;Mean Change from Baseline (+SE)&#160;&#160;n=&#160;&#160;29&#160;&#160;16&#160;&#160;20&#160;&#160;19&#160;&#160;15&#160;&#160;95%
              CI=&#160;&#160;(-0.1,&#8201;2.0)&#160;&#160;(-0.5,&#8201;2.1)&#160;&#160;(0.5,&#8201;3.2)&#160;&#160;(-0.8,&#8201;4.2)&#160;&#160;Pooled Nonambulatory Patients &#160;&#160;Age 2-21 YearsAll Doses (N=35)&#160;&#160;Age 2-12 YearsAll Doses (N=29)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide56.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;PEDI-CAT Daily Activities Over 36 Months Improvements Were Substantial and
              Sustained&#160;&#160;56&#160;&#160;For the 36-month evaluation, an observed case analysis was conducted, which pooled all the nonambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis population included
              patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). Error bars represent SE. CI represents confidence interval. SMN Rx=SMN
              therapy. Data cutoff date as of March 13, 2023. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health
              authority, and its safety and efficacy have not been established.&#160;&#160;Baseline mean age=7.3 |&#8202;Time on SMN Rx=24.1m &#160;&#160;Baseline mean age=5.5 |&#8202;Time on SMN Rx=24.6m &#160;&#160;n=&#160;&#160;35&#160;&#160;21&#160;&#160;25&#160;&#160;23&#160;&#160;17&#160;&#160;95%
              CI=&#160;&#160;(-0.0,&#8201;2.6)&#160;&#160;(-0.1,&#8201;2.6)&#160;&#160;(0.9,&#8201;3.5)&#160;&#160;(-0.1,&#8201;4.5)&#160;&#160;Mean Change from Baseline (+SE)&#160;&#160;n=&#160;&#160;29&#160;&#160;16&#160;&#160;20&#160;&#160;19&#160;&#160;15&#160;&#160;95% CI=&#160;&#160;(-0.1,&#8201;2.0)&#160;&#160;(-0.5,&#8201;2.1)&#160;&#160;(0.5,&#8201;3.2)&#160;&#160;(-0.8,&#8201;4.2)&#160;&#160;Pooled Nonambulatory Patients &#160;&#160;Age 2-21 YearsAll Doses (N=35)&#160;&#160;Age
              2-12 YearsAll Doses (N=29)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide57.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;PROMIS Fatigue (Proxy) Over 36 Months Improvements Were Substantial and
              Sustained&#160;&#160;57&#160;&#160;For the 36-month evaluation, an observed case analysis was conducted, which pooled all the nonambulatory patients (Cohorts 2 and 3) and was based upon the available data for given timepoints. This analysis population included
              patients receiving either low dose (2 mg/kg) or high dose (20 mg/kg) apitegromab (inclusive of patients in Cohort 3 who switched from 2 mg/kg to 20 mg/kg in Year 2). Error bars represent SE. CI represents confidence interval. SMN Rx=SMN
              therapy. Data cutoff date as of March 13, 2023. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health
              authority, and its safety and efficacy have not been established.&#160;&#160;Mean Change from Baseline (+SE)&#160;&#160;Pooled Nonambulatory Patients &#160;&#160;n=&#160;&#160;35&#160;&#160;19&#160;&#160;17&#160;&#160;20&#160;&#160;14&#160;&#160;95%
              CI=&#160;&#160;(-4.3,&#8201;1.4)&#160;&#160;(-5.7,&#8201;0.8)&#160;&#160;(-6.0,&#8201;-0.3)&#160;&#160;(-8.7,&#8201;-0.5)&#160;&#160;n=&#160;&#160;29&#160;&#160;15&#160;&#160;13&#160;&#160;17&#160;&#160;12&#160;&#160;95% CI=&#160;&#160;(-3.7. 2.8)&#160;&#160;(-6.0, 0.2)&#160;&#160;(-6.0. 0.1)&#160;&#160;(-8.9,&#8201;0.4)&#160;&#160;Baseline mean age=7.3 |&#8202;Time on SMN Rx=24.1m &#160;&#160;Baseline mean age=5.5 |&#8202;Time on SMN Rx=24.6m &#160;&#160;Age
              2-21 YearsAll Doses (N=35)&#160;&#160;Age 2-12 YearsAll Doses (N=29)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide58.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ Topline 12-Month Data Showed Apitegromab&#8217;s Transformative Potential in
              Patients with Type 2/3 SMA&#160;&#160;58&#160;&#160;Crawford T et al. TOPAZ topline results; Presented at CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021&#160;&#160;* Pooled cohorts of nonambulatory patients treated with apitegromab 20
              mg/kg and 2 mg/kg&#160;&#160;**Nonambulatory patients who initiated background nusinersen at a young age of &lt;5 years and treated with apitegromab 20 mg/kg dose. Apitegromab is an investigational drug candidate being evaluated for the treatment of
              spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;HFMSE change from baseline&#160;&#160;Majority of nonambulatory patients*
              experienced HFMSE increases from apitegromabduring chronic maintenance phase of SMN therapy&#160;&#160;Apitegromab led to HFMSE improvements in both nonambulatory cohortsincluding patients started on nusinersen at age &#8805; 5&#160;&#160;Initiated background
              nusinersen &#160;&#160;Age &lt; 5**&#160;&#160;Age &#8805; 5&#160;&#160;Mean HFMSE Increase&#160;&#160;+7.1 points&#160;&#160;+0.6 points&#160;&#160;&#8805; 1-point Increase % (n/N)&#160;&#160;88% (7/8)&#160;&#160;64% (9/14)&#160;&#160;&#8805; 3-point Increase% (n/N)&#160;&#160;63% (5/8)&#160;&#160;29% (4/14)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide59.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ Age 2-12 Analysis* in Pooled Nonambulatory Cohorts (20mg/kg) at 12 Months
              Mean Increase of Motor Function Outcomes by HFMSE was Significant &#160;&#160;59&#160;&#160;Mean HFMSE Increase&#160;&#160;OF 4.4 POINTS&#160;&#160;with majority experiencing &#8805; 3-point increases on top of background SMN therapy&#160;&#160;HFMSE Gains Also Notable&#160;&#160;in subset of individuals in
              this analysis who had started background nusinersen at age &#8805; 5: &#160;&#160;75% (6/8) with &#8805; 1-point increase&#160;&#160;50% (4/8) with &#8805; 3-point increase&#160;&#160;Nonambulatory Types 2/3 SMA&#160;&#160;(Apitegromab 20 mg/kg; Intent-to-Treat Population)&#160;&#160;Age 2-12
              years&#160;&#160;(n=16&#8224;)&#160;&#160;Mean HFMSE change from baseline, (95% CI)&#160;&#160;+4.4 (1.3, 7.4)&#160;&#160;Patients with &#8805; 1-pt increase in HFMSE, n (%)&#160;&#160;13 (81%)&#160;&#160;Patients with &#8805; 3-pt increase in HFMSE, n (%)&#160;&#160;9 (56%)&#160;&#160;TOPAZ results showed HFMSE improvement from baseline
              or RHS stabilization across all three pre-specified cohorts.1&#160;&#160;No safety signals for apitegromab were identified through month 12 of TOPAZ; the five most frequently reported treatment-emergent adverse events were headache, pyrexia, upper
              respiratory tract infection, cough, and nasopharyngitis&#160;&#160;*Exploratory, post hoc analysis. &#8224;For 12-month endpoint, if participants skipped three consecutive doses due to site restrictions caused by COVID-19, records after dose skipping were
              excluded from analysis. The last observation carried forward was used for other missing data.&#160;&#160;1. Crawford T et al. TOPAZ topline results. Presented at Muscular Dystrophy Association, 2023 Clinical &amp; Scientific Conference, March 22, 2023.
              CI, confidence interval; HFMSE, Hammersmith functional motor scale expanded; SMA, spinal muscular atrophy. Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been
              approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide60.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ 12-Month Data | Nonambulatory Type 2 High Dose CohortInitiated nusinersen
              age &lt;51,2&#160;&#160;60&#160;&#160;Increases in HFMSE observed in patients already treated with chronic maintenance nusinersen&#160;&#160;Improved: 88% (7/8)&#160;&#160;&#8805; 5-point increase: 63% (5/8)&#160;&#160;&gt; 10-point increase: 38% (3/8)&#160;&#160;Continuous and durableimprovements observed
              through12-months of treatment&#160;&#160;Apitegromab (20 mg/kg) + nusinersen&#160;&#160;n=8*&#160;&#160;Mean change from baseline in HFMSE&#160;&#160;(95% CI)&#160;&#160;+7.1&#160;&#160;&#160;(1.8, 12.5)&#160;&#160;# (%) patients achieving:&#160;&#160;&#8805; 1-pt increase in HFMSE&#160;&#160;7/8 (88%)&#160;&#160;&#8805; 3-pt increase in HFMSE&#160;&#160;5/8 (63%)&#160;&#160;&#8805;
              5-pt increase in HFMSE&#160;&#160;5/8 (63%)&#160;&#160;Baseline characteristics: mean (min, max)&#160;&#160;n=10&#160;&#160;Age&#160;&#160;3.8 (2, 6)&#160;&#160;HFMSE score&#160;&#160;23.5 (14, 42)&#160;&#160;# of nusinersen maintenance doses&#160;&#160;5.4 (3, 8)&#160;&#160;*This was a primary intent-to-treat (ITT) analysis that, as
              prespecified, excluded 2 patients who missed 3 doses due to COVID-19 related site access restrictions. An all-patients sensitivity analysis that included those 2 patients had similar results as this primary ITT analysis.&#160;&#160;&#160;Crawford T et al.
              TOPAZ topline results; Presented at&#160;CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021. 2. Data on file; Scholar Rock. 2022.&#160;&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of
              spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide61.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ 12-Month Data | Nonambulatory Type 2/3 CohortInitiated nusinersen age
              &#8805;51,2&#160;&#160;61&#160;&#160;Majority of patients improved in HFMSE (despite initiating background nusinersen age &#8805; 5)&#160;&#160;&#8805; 1-point increase: ~67%&#160;&#160;&#8805; 3-point increase: ~30%&#160;&#160;Durability of effect observed through 12-months of treatment&#160;&#160;*Intent-to-treat analysis
              excluded 1 patient (per prespecified approach) who missed 3 doses due to COVID-19 related site access restrictions; 1 patient who had inadvertently been enrolled who was receiving (and continued to receive) an acetylcholinesterase inhibitor
              was removed, which is not permitted per the trial protocol; 1.&#160;Crawford T et al. TOPAZ topline results; Presented at&#160;CureSMA, 2021 Virtual SMA Research &amp; Clinical Care Meeting; June 9-11, 2021. 2. Data on file. Scholar Rock,
              Inc.&#160;Apitegromab is an investigational drug candidate being evaluated for the treatment of spinal muscular atrophy. Apitegromab has not been approved for any use by the US FDA or any other health authority, and its safety and efficacy have
              not been established.&#160;&#160;Apitegromab (20 mg/kg) + nusinersen&#160;&#160;Per Protocol Population* &#160;&#160;(n=13)&#160;&#160;Intent-to-Treat Population&#160;&#160;(n=14)&#160;&#160;Mean change from baseline in HFMSE &#160;&#160;(95% CI)&#160;&#160;+1.2 &#160;&#160;(-0.5, 2.9)&#160;&#160;+0.6&#160;&#160; (-1.4, 2.7)&#160;&#160;# (%) patients
              achieving:&#160;&#160;&#8805; 1-pt increase in HFMSE&#160;&#160;9/13 (69%)&#160;&#160;9/14 (64%)&#160;&#160;&#8805; 3-pt increase in HFMSE&#160;&#160;4/13 (31%)&#160;&#160;4/14 (29%)&#160;&#160;&#8805; 5-pt increase in HFMSE&#160;&#160;2/13 (15%)&#160;&#160;2/14 (14%)&#160;&#160;Baseline characteristics: mean (min, max)&#160;&#160;n=15&#160;&#160;Age&#160;&#160;11.7 (8, 19)&#160;&#160;HFMSE
              score&#160;&#160;22.7 (13, 39)&#160;&#160;# of nusinersen maintenance doses&#160;&#160;5.1 (2, 9)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide62.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TOPAZ 12-Month HFMSE Changes and Duration of Prior Nusinersen&#160;&#160;62&#160;&#160;Patients
              enrolled were already in the chronic maintenance phase of nusinersen&#160;&#160;Lack of clear correlation between 12-month HFMSE &amp; duration of prior nusinersen exposure in patients aged 2 &#8211; 21 suggests motor function improvement mainly attributable
              to apitegromab&#160;&#160;Post hoc analysis: Scatter plot of prior nusinersen treatment duration vs change in HFMSE from baseline; in nonambulatory Types 2 and 3 participants in TOPAZ, there was no clear relationship between duration of nusinersen
              treatment and change in motor function. Patients skipped 3 or more doses due to COVID-site restrictions excluded; apitegromab is an investigational product candidate under development. HFMSE, Hammersmith Functional Motor Scale&#8211;Expanded&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide63.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;1. Mercuri E, et.al. Nusinersen versus sham control in later-onset spinal
              muscular atrophy. N Engl J Med. 2018;378:625-635.&#160;&#160;2. Efficacy and safety of risdiplam (RG7916) in patients with Type 2 or non-ambulant Type 3 spinal muscular atrophy (SMA) Roche/PTC Therapeutics&#160;&#160;This third-party information is provided for
              background only and is not intended to convey or imply a comparison to the TOPAZ clinical trial results&#160;&#160;Nusinersen CHERISH Trial in Later-Onset SMA1&#160;&#160;In patients with later-onset SMA who were age &gt;5 at screening:&#160;&#160;Primary benefit of
              nusinersen: stabilization of motor function&#160;&#160;Majority of patients do not experience HFMSE increases&#160;&#160;Nonambulatory Type 2/3 SMA Majority of Patients Started on SMN Therapy After Age 5 Do Not Experience Motor Function Increases&#160;&#160;63&#160;&#160;Risdiplam
              SUNFISH Trial in Later-Onset SMA2&#160;&#160;Low percentage of patients over the age of 5 achieved &#8805;3-point increase on MFM32 scale, even with risdiplam treatment&#160;&#160;HFMSE secondary endpoint showed a mean 0.58-point improvement over placebo (not
              statistically significant) &#160;&#160;Change &#160;From Baseline&#160;&#160;to 15 Months in HFMSE Score&#160;&#160;&#160;Age, year&#160;&#160;2&#160;&#160;4&#160;&#160;6&#160;&#160;8&#160;&#160;Nusinersen (N=66)&#160;&#160;Control (N=34)&#160;&#160;% of patients with &gt; 3 change in &#160;&#160;MFM32 total at Month 12&#160;&#160;Change in MFM32 total score&#160;&#160;2-5
              Years&#160;&#160;6-11 Years&#160;&#160;12-17 Years&#160;&#160;18-25 Years&#160;&#160;Risdiplam&#160;&#160;Placebo&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide64.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Significance of Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised
              Upper Limb Module (RULM)&#160;&#160;64&#160;&#160;HFMSE&#160;&#160;Assesses the physical abilities of patients with Types 2/3 SMA&#160;&#160;ABLE TO:&#160;&#160;Touch Head Above Ear Level&#160;&#160;whilst maintaining stable trunk and head&#160;&#160;Roll From Supine to Prone&#160;&#160;over the right side without
              pulling/ pushing on hands&#160;&#160;33 Items&#160;&#160;Graded on scale 0 to 2&#160;&#160;0 = unable&#160;&#160;1 = performed with modification or adaptation&#160;&#160;2 = without modification or adaptation &#160;&#160;Item scores are summed to give a total score &#160;&#160;The higher the total score, the
              greater the patient&#8217;s motor function&#160;&#160;Maximum score: 66&#160;&#160;Examples of items:&#160;&#160;One hand to head in sitting&#160;&#160;Rolls supine to prone&#160;&#160;Lying to sitting&#160;&#160;Four&#8211;point kneeling&#160;&#160;Supported standing&#160;&#160;Stepping&#160;&#160;Ascends 4 stairs with
              railing&#160;&#160;RULM&#160;&#160;Evaluates Motor Performance in Upper Limbs&#160;&#160;ABLE TO:&#160;&#160;Bring Token&#160;&#160;to Cup&#160;&#160;placed vertically at shoulder height&#160;&#160;Bring Weight at Eye Level using two hands&#160;&#160;19 Items&#160;&#160;Graded on scale 0 to 2(Except for 1 activity with a binary
              score)&#160;&#160;0 = unable&#160;&#160;1 = able with modification&#160;&#160;2 = able with no difficulty&#160;&#160;Evaluated upper limb tasks correspond to ability to perform everyday activities&#160;&#160;Maximum score: 37&#160;&#160;Examples of items:&#160;&#160;Putting a coin into a cup&#160;&#160;Elevating a cup to
              mouth&#160;&#160;Picking up a coin&#160;&#160;Bringing hand to shoulder&#160;&#160;Lifting up weighted objects&#160;&#160;Opening a zip lock bag &#160;&#160;Drawing a line on paper&#160;&#160;O&#8217;Hagen et al. 2007; Glanzman et al. 2011; Hammersmith Functional Motor Scale Expanded for SMA (HFMSE) Manual,
              2019&#160;&#160;Mazzone et al. 2017; Pierzchlewicz et al. 2021; Revised Upper Limb Module for SMA Manual, 2014 &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide65.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;PEDI-CAT:&#160;&#160;Measure of activities of daily living&#160;&#160;PROMIS (Fatigue):&#160;&#160;Measure of
              Patient Fatigue &#160;&#160;ESBBT (Fatigability):&#160;&#160;Measure of how fast a patient fatigues&#160;&#160;1&#160;&#160;2&#160;&#160;3&#160;&#160;PRO measurement tool4&#160;&#160;Muscle endurance measurement tool6&#160;&#160;4-point scale (1=unable to 4=easy) assessment of various activities, higher scores reflect
              improved abilities1,2&#160;&#160;PEDI-CAT has been validated in SMA, but alone cannot identify small changes in function across all types of SMA3&#160;&#160;Measures mild subjective feelings of tiredness to debilitating and sustained feelings of exhaustion, with
              lower scores reflecting less fatigue4,5&#160;&#160;Has been utilized to assess fatigue and fatigability in the Cure SMA database, but has not been fully validated in SMA5&#160;&#160;Part of a series of endurance shuttle tests that include: nine-hole peg test,
              box and block test, and walk test (ESNHPT, ESBBT, and ESWT)6&#160;&#160;Patients are asked to move blocks individually from one box to another in one minute, with higher numbers of blocks suggesting higher muscle endurance6&#160;&#160;The endurance shuttle tests
              have been validated for use in patients with SMA7&#160;&#160;Measures pediatric abilities through 3 functional domains, daily activities, mobility, and social cognitive1&#160;&#160;Activities of Daily Living and Fatigue: Assessed by Three Measures&#160;&#160;65&#160;&#160;ADL,
              activities of daily living; ESBBT, endurance shuttle box and block test; ESNHPT, endurance shuttle nine-hole peg test; ESWT, endurance shuttle walk test; PEDI-CAT, pediatric evaluation of disability inventory computer adaptive test; PROMIS,
              patient-reported outcomes measurement information system; PRO(s), patient-reported outcome(s); SMA, spinal muscular atrophy. 1. Cre Care. PEDI-CAT. Accessed April 26, 2022. https://www.pedicat.com/. 2. Data on file; Scholar Rock. 2022. 3.
              Pasternak A, et al. Muscle Nerve. 2016;54(6):1097-1107. 4. NIH. PROMIS. Accessed April 26, 2022. https://commonfund.nih.gov/promis/index. 5. Belter L, et al. Orphanet Journal of Rare Diseases. 2020;15:217. 6. Cure SMA. Best Practices for
              Physical Therapists and Clinical Evaluators in Spinal Muscular Atrophy (SMA). 2021. Available at: https://www.curesma.org/wp-content/uploads/2021/09/Clinical-Evaluators-Best-Practices-13-August-2021.pdf. 7. Bartels B, et al. Orphanet Journal
              of Rare Diseases. 2020;15:75. &#160;&#160;PEDI-CAT, PROMIS, and ESBBT &#160;&#160;Used to assess:&#160;&#160;ADL&#160;&#160;Fatigue&#160;&#160;Muscle Endurance&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide66.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Reported Impact of Scoliosis Surgery on Motor Abilities in SMA&#160;&#160;66&#160;&#160;Dunaway
              Young et al. 2020&#160;&#160;Scoliosis Surgery&#160;&#160;HFMSE Total Score&#160;&#160;3-month post-surgery assessment&#160;&#160;14/17&#160;&#160;Lost &gt;3 points on the HFMSE (mean change = - 12.1, SD = 8.9) &#160;&#160;Functionally meaningful change &#160;&#160;13/17&#160;&#160;Minimal HFMSE changes within &#177; 2 points
              (mean change = - 0.7)&#160;&#160;No change or stability&#160;&#160;0/17&#160;&#160;Improvement &gt; 2 points post-surgery&#160;&#160;Post-Surgery HFMSE scores Type 2/3 SMApeer-reviewed study &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide67.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181: Transformative Potential as the Backbone For Next Era of Cancer
              Therapy&#160;&#160;67&#160;&#160;CPI Combination&#160;&#160;(solid tumors)&#160;&#160;Other Combinations (solid tumors)&#160;&#160;&amp; Hematologic&#160;&#160;Other immunotherapies&#160;&#160;Chemotherapy &#160;&#160;XRT&#160;&#160;Otherapplications&#160;&#160;Myelofibrosis&#160;&#160;Liquid tumors&#160;&#160;1st line immunotherapy&#160;&#160;First in class&#160;monoclonal
              antibody targeting&#160;latent&#160;and context-independent&#160;binding to TGFB-1&#160;&#160;CURRENT FOCUS&#160;&#160;Primary and AcquiredCPI resistance&#160;&#160;Investigation in primary (pre-existing) CPI resistance offers path to early clinical POC for SRK-181&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide68.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Regulatory T cell&#160;&#160;Tumor Associated &#160;&#160;Macrophage&#160;&#160;Cancer Associated Fibroblasts
              (Stromal cells)&#160;&#160;Tumor cells&#160;&#160;SRK-181 Attributes&#160;&#160;Targets latent TGF&#946;-1 &#160;&#160;Inhibits activation of latent TGF&#946;-1 across ALL compartments&#160;&#160;Turns it off at the source&#160;&#160;Context-Independent: SRK-181 Designed to Inhibit Latent TGF&#946;-1 Across All
              Compartments of the Tumor Microenvironment&#160;&#160;68&#160;&#160;Latent TGF&#946;-1&#160;&#160;Key driver of tumor resistance to CPIs &#160;&#160;Present in multiple compartments of the tumor microenvironment&#160;&#160;TGF&#946; Latent growth factor&#160;&#160;TGF&#946; source
              presentation&#160;&#160;LRRC33&#160;&#160;GARP&#160;&#160;LTBPs&#160;&#160;LTBPs&#160;&#160;LRRC33: leucine-rich-repeat-containing protein family member 33 | LTBPs: latent transforming growth factor &#946; binding proteins | GARP: glycoprotein A repetitions predominant&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide69.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181 Therapeutic Hypothesis: Potential Advantages of Latent TGF&#946;-1
              Inhibitor&#160;&#160;69&#160;&#160;SRK-181*&#160;&#160;Bifunctional TGF&#946;/CPI &#160;&#160;ALK5 Inhibitor&#160;&#160;Nonselective TGF&#946; antibody&#160;&#160;Selectivity for TGF&#946;-1: potential for wider therapeutic window and improved safety&#160;&#160;Ability to combine with any anti-PD-(L)1&#160;&#160; &#160;&#160; &#160;&#160;Ability to
              optimize dosing of each component of combination therapy&#160;&#160;Activity spatially distinct from anti-PD-(L)1 in tissue&#160;&#160; &#160;&#160;Inhibits all sources of TGF&#946;-1 contributing to CPI resistance (Context independent)&#160;&#160;Target latent form (Blocks TGF&#946;-1
              activation)&#160;&#160;*SRK-181 is an investigational product candidate currently being evaluated in DRAGON phase 1 clinical trial. The efficacy and safety of SRK-181 have not been established. &#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;&#160;X&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide70.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;TGF&#946;-1 Blockade with SRK-181-mIgG1 Rendered Preclinical Tumor Models Susceptible
              to Anti-PD1 Therapy&#160;&#160;70&#160;&#160;Days after treatment initiation&#160;&#160;Tumor volume (mm3)&#160;&#160;Anti-PD1/&#160;&#160;SRK-181-mIgG1(3 mg/kg QW)&#160;&#160;4/14&#160;&#160;Anti-PD1/&#160;&#160;SRK-181-mIgG1(10 mg/kg QW)&#160;&#160;8/14&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et
              al. Sci Transl Med. 2020 Mar 25;12(536):eaay8456. https://scholarrock.com/platform/publications/.&#160;&#160;*SRK-181-mIgG1 is the murine version of SRK-181; responder defined as tumor size &lt;25% endpoint volume at study end.&#160;&#160;Bladder Cancer&#160;&#160;Breast
              Cancer (TGF&#946;-1/3 co-expressing)&#160;&#160;0/13&#160;&#160;Anti-PD1 (10 mg/kg BIW)&#160;&#160;0/10&#160;&#160;SRK-181-mIgG1* (10 mg/kg QW)&#160;&#160;Anti-PD1/&#160;&#160;SRK-181-mIgG1(10 mg/kg QW)&#160;&#160;5/10&#160;&#160;Responders 0/9&#160;&#160;Control&#160;&#160;0/9&#160;&#160;Anti-PD1 (10 mg/kg BIW)&#160;&#160;SRK-181-mIgG1* (10 mg/kg QW)&#160;&#160;Responders
              0/12&#160;&#160;MBT-2 and EMT6 Models &#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide71.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;SRK-181-mIgG1 Combination Treatment Led to Melanoma Tumor Regression and
              Survival Benefit &#160;&#160;71&#160;&#160;*P&lt;0.01. &#160;&#160;&#8224;P&lt;0.05 Log-rank (Mantel-Cox test) vs anti-PD1.&#160;&#160;*&#160;&#160;*&#160;&#160;&#8224;&#160;&#160;Days after treatment initiation&#160;&#160;Tumor Regression&#160;&#160;Survival Benefit&#160;&#160;Anti-PD1 + SRK-181-mlgG1 (30 mg/Kg/wk)&#160;&#160;Anti-PD1 + SRK-181-mlgG1 (3
              mg/Kg/wk)&#160;&#160;Anti-PD1 + SRK-181-mlgG1 (10 mg/Kg/wk)&#160;&#160;Anti-PD1 (10 mg/Kg/2xwk)&#160;&#160;SRK-181-mlgG1 (30 mg/Kg/wk)&#160;&#160;Control&#160;&#160;Melanoma (Cloudman S91) model&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med.
              2020 Mar 25;12(536):eaay8456. https://scholarrock.com/platform/publications.&#160;&#160;Days after treatment initiation&#160;&#160;Monotherapy&#160;&#160;3/12&#160;&#160;Anti-PD1&#160;&#160;(10 mg/kg BIW)&#160;&#160;Tumor volume (mm3)&#160;&#160;SRK-181-mIgG1&#160;&#160;(30 mg/kg QW)&#160;&#160;Responders 0/12&#160;&#160;Combination
              Therapy&#160;&#160;Led to tumor regression and survival benefit&#160;&#160;Anti-PD1/SRK-181-mIgG1 (30 mg/kg QW)&#160;&#160;8/11&#160;&#160;Days after treatment initiation&#160;&#160;Anti-PD1/SRK-181-mIgG1 (10 mg/kg QW)&#160;&#160;Tumor volume (mm3)&#160;&#160;4/9&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide72.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Selectivity of SRK-181 Offers Potential to Overcome Toxicity and Dose-limiting
              Challenges of Non-selective TGF&#946; Pathway Approaches &#160;&#160;72&#160;&#160;Preclinical data published in Science Translational Medicine. Martin CJ, et al. Sci Transl Med 2020 Mar 25;12(536): eaay8456. &#160;&#160;*Source: Anderton MJ, et al. Induction of heart valve
              lesions by small-molecule ALK5 inhibitors. Toxicol Pathol. 2011;39: 916-924.; and Stauber AJ, et al. Nonclinical safety evaluation of a transforming growth factor &#946; Receptor I kinase inhibitor in Fischer 344 rats and beagle dogs. J Clin
              Pract. 2014: 4:3.&#160;&#160;Microscopic Observations in Heart&#160;&#160;Valvulopathy&#160;&#160;Atrium&#8212;Mixed cell infiltrate&#160;&#160;Myocardium&#8212;Degeneration/necrosis&#160;&#160;Myocardium&#8212;Hemorrhage&#160;&#160;Myocardium&#8212;Mixed cell infiltrate, base&#160;&#160;Coronary artery&#8212;Necrosis with
              inflammation&#160;&#160;Cardiomyocyte&#8212;Necrosis/inflammatory cell infiltrate&#160;&#160;CONTROL&#160;&#160;Vehicle&#160;&#160;iv, qwk x 4&#160;&#160;LY2109761&#160;&#160;300 mg/kg&#160;&#160;po, qd x 8&#160;&#160;PanTGF&#946;Ab&#160;&#160;30 mg/kg&#160;&#160;Iv, 1 dose&#160;&#160;10 mg/kg&#160;&#160;iv, qwk x 4&#160;&#160;30 mg/kg&#160;&#160;iv, qwk x 4&#160;&#160;100 mg/kg&#160;&#160;iv, qwk x
              4&#160;&#160;SRK-181&#160;&#160;Selective TGF&#946;-1 Toxicity: Minimal&#160;&#160;Non-selective TGF&#946;&#160;&#160;Toxicity: Minimal, slight and moderate&#160;&#160;Unremarkable&#160;&#160;Minimal&#160;&#160;Slight&#160;&#160;Moderate&#160;&#160;Toxicology:&#160;&#160;Repeat Dose Pilot Toxicology Study&#160;&#160;Adult female Sprague Dawley rats&#160;&#160;Cardiac
              findings were exhibited&#160;&#160;in animals dosed with pan-TGF&#946; antibody or LY2109761 (inhibitor of ALK5, common TGF&#946; receptor kinase) as expected based on published data&#8224;&#160;&#160;NO CARDIOTOXICITIES (valvulopathy)were noted with SRK-181 &#160;&#160;NOAEL for
              SRK-181: 100 mg/kg QW(highest dose evaluated)&#160;&#160;4-week GLP toxicology studies&#160;&#160;RATS&#160;&#160;NOAEL for SRK-181: 200 mg/kg QW (highest dose evaluated)&#160;&#160;NON-HUMAN PRIMATES&#160;&#160;NOAEL for SRK-181: 300 mg/kg(highest dose evaluated)&#160;&#160;Not test article related&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide73.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Bladder urothelial carcinoma&#160;&#160;Had &amp; neck squamous carcinoma&#160;&#160;Kidney clear
              cell carcinoma&#160;&#160;Kidney papillary cell carcinoma&#160;&#160;Liver hepatocellular carcinoma&#160;&#160;Lung adenocarcinoma&#160;&#160;Skin cutaneous melanoma&#160;&#160;Stomach adenocarcinoma&#160;&#160;Acute myeloid leukemia&#160;&#160;Adrenocortical cancer&#160;&#160;Brain lower grade glioma&#160;&#160;Breast invasive
              carcinoma&#160;&#160;Cervical &amp; endocervical cancer&#160;&#160;Cholangiocarcinoma&#160;&#160;Colon adenocarcinoma&#160;&#160;Diffuse large B-cell carcinoma&#160;&#160;Esophageal carcinoma&#160;&#160;Glioblastoma multiforme&#160;&#160;Kidney chromophobe&#160;&#160;Lung squamous cell carcinoma&#160;&#160;Mesothelioma&#160;&#160;Ovarian
              serous cystadenocarcinoma&#160;&#160;Pancreatic adenocarcinoma&#160;&#160;Pheochromocytoma &amp; paraganglioma&#160;&#160;Prostate adenocarcinoma&#160;&#160;Emerging Evidence Implicates TGF&#946;-1 as Driving Primary Resistance to Checkpoint Inhibitors&#160;&#160;73&#160;&#160;Human Tumor Analyses Reveal
              TGF&#946;-1 as Most Likely Driver of TGF&#946; Signaling Pathway in Cancers&#160;&#160;&#8224;Priti H, et al. Top 10 challenges in cancer immunotherapy. Immunity. 2020 Jan 14:52(1):17-35. https://doi.org/10.1016/j.immuni.2019.12.011.&#160;&#160;*Source: National Cancer
              Institute - Cancer Genome Atlas Program.&#160;&#160;NSCLC&#160;&#160;TMB&#160;&#160;Low&#160;&#160;High&#160;&#160;Substantial % of Solid Tumors Exhibit Immune Exclusion&#160;&#160;Immune Excluded&#160;&#160;Immune Phenotype&#160;&#160;Inflamed&#160;&#160;Immune Desert&#160;&#160;Tumor Type&#160;&#160;Melanoma&#160;&#160;RCC&#160;&#160;UBC&#160;&#160;TNBC&#160;&#160;Gastric&#160;&#160;CRC
              MSS&#160;&#160;Pancreatic&#160;&#160;SCLC&#160;&#160;HR+BC&#160;&#160;Prostate&#160;&#160;Immune Excluded&#160;&#160;Inflamed&#160;&#160;Immune Desert&#160;&#160;Cancer Genome Atlas RNAseq Analysis of &gt;10,000 Samples Spanning 33 Tumor Types*&#160;&#160;TGFB1&#160;&#160;TGFB2&#160;&#160;TGFB3&#160;&#160;Scale&#160;&#160;% of patient samples (+)&#160;&#160;for TGF-&#946;
              isoform&#160;&#160;100&#160;&#160;80&#160;&#160;60&#160;&#160;40&#160;&#160;20&#160;&#160;0&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide74.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Biomarker Strategies Employed in DRAGON Trial&#160;&#160;74&#160;&#160;Multiple tissue-based and
              circulating biomarker analyses to be evaluated in DRAGON study&#160;&#160;Higher resolution histochemical characterization of tumor immune contexture (e.g. CD8+)&#160;&#160;Classification of inflamed, excluded or immune desert tumors and tumor nests&#160;&#160;Ability of
              SRK-181 to overcome tumor immune exclusion&#160;&#160;Analysis of immune response markers (e.g. PD-L1)&#160;&#160;Changes to intra-tumoral and/or circulating immune cell contexture (MDSC)&#160;&#160;Show evidence of the SRK-181 target engagement&#160;&#160;e.g. circulating TGF&#946;-1
              levels&#160;&#160;TGF&#946; pathway modulation:&#160;&#160;e.g. Histochemical analysis of pSMAD&#160;&#160;e.g. RNA-based TGF&#946; gene signatures and pathway analyses&#160;&#160;Paired biopsies from the head and neck cohort allow for a potential to accelerate the development
              path&#160;&#160;Immunophenotyping&#160;&#160;Assessment of immune landscape&#160;&#160;TGF&#946;-1 pathway evaluation&#160;&#160;Assessment of signaling pathway&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide75.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Clear Evidence of Target EngagementPharmacodynamic Biomarker Results for Part A:
              Circulatory TGF&#946;-1&#160;&#160;75&#160;&#160;Yap T et al. SRK-181, a latent TGF&#946;1 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors (Poster 780); Presented
              at SITC; Nov. 10-11, 2022. Circulatory TGF&#946;-1 and PF4 levels were quantitated by using validated ELISA kits from R&amp;D System.12 Because platelet activation during sample processing can lead to elevated TGF&#946;-1 levels, samples with elevated
              PF4, a platelet activation biomarker, were excluded from the analysis based on a preliminary cutoff value.&#160;&#160;Pre-infusion.&#160;&#160;SRK-181 is an investigational drug candidate that is being evaluated for the treatment of cancer. SRK-181 has not been
              approved by the US FDA or any other health authority, and its safety and efficacy have not been established.&#160;&#160;Binding to latent TGF&#946;-1 delays maturity state allowing TGF&#946;-1 to accumulate in system&#160;&#160;Combination treatment with pembrolizumab did
              not appear to impact circulatory TGF&#946;-1 levels&#160;&#160;C1D2&#160;&#160;C1D8&#160;&#160;C1D15&#160;&#160;C2D1*&#160;&#160;C3D1*&#160;&#160;C3D2&#160;&#160;C3D8&#160;&#160;C3D15&#160;&#160;C4D1*&#160;&#160;C5D1*&#160;&#160;Baseline&#160;&#160;Circulatory TGF&#946;-1&#160;&#160;(Fold-Change from Baseline)&#160;&#160;2&#160;&#160;3&#160;&#160;4&#160;&#160;6&#160;&#160;5&#160;&#160;Median Circulatory TGF&#946;-1 Increased Post-treatment
              with SRK-181 (Q3W, All Patients)&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt; margin-left: 0pt; margin-right: 0pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="background-color: #000000; border-width: 0px; clear: both; color: #000000; height: 2px; margin: 4px 0px; width: 100%;"></div>
      </div>
      <div style="text-align: center;" class="slide">
        <div style="position: relative; left: 0px; top: 0px;" class="frame">
          <div style="left: 0px; top: 0px;"><img src="../../../cdn.kscope.io/549c4ee5c448fa06db2f27bd8f9cfcf5-a53438186_ex992slide76.jpg"></div>
        </div>
        <div style="text-align: center;" class="slideText">
          <div style="text-align: left;" class="slideTextFrame"><font style="color: white; display: inline; font-family: '\'Times New Roman\'', Times, serif; font-size: 1pt;">&#160;Preclinical Data Provide Scientific Rationale to Evaluate Peripheral Samples for
              Evidence of SRK-181 Activity&#160;&#160;76&#160;&#160;MBT-2 bladder tumor model IgG, anti-PD-1 and SRK-181-mIgG1 dosed d1, d7&#160;&#160;Analysis on day 10&#160;&#160;Circulating MDSC Levels Correlate&#160;&#160;with Tumor Volume&#160;&#160;Both tumoral and circulatory MDSC are being evaluated in the
              DRAGON study&#160;&#160;Immunophenotyping&#160;&#160;Assessment of immune landscape&#160;&#160;Measurement of MDSCs in circulation may provide indirect evidence of drug action on the tumor&#160;&#160;Myeloid-derived suppressor cells (MDSCs) have immune suppressive
              functions&#160;&#160;SRK-181 plus anti-PD1 combination drive MDSC levels down significantly in the tumor microenvironment&#160;&#160;Reductions in circulating MDSC levels correlate with reduced tumor volume following SRK-181 and anti-PD1 treatment in MBT-2 tumor
              model&#160;&#160;Anti-PD-1+&#160;&#160;SRK-181&#160;&#160; 1 mpk&#160;&#160; 3 mpk&#160;&#160; 10 mpk&#160;&#160;IgG Ctrl&#160;&#160;SRK-181&#160;&#160;Anti-PD-1&#160;</font></div>
        </div>
      </div>
      <div style="text-align: center;" class="spaceAfterSlideText">&#160;</div>
    </font></div>
</body>
</html>


  </div>

  </div>

          <script type="text/javascript">var s_CCSWebHostingAccount = "trcgscholarrock";</script>
        <script type="application/json" data-drupal-selector="drupal-settings-json">{"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/9561\/html","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb56236\/themes\/site\/nir_pid2662"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"user":{"uid":0,"permissionsHash":"4506f7b957b4baf2488ee006e9b884f3b49293f46cfb6e03ffbb15fedba12da4"}}</script>
<script src="../../sites/g/files/knoqqb56236/files/js/js_D31miEwayYNfIODJWy2ump8i_gwklTzvOKq4eFgXiKw4996.js?scope=footer&amp;delta=0&amp;language=en&amp;theme=nir_pid2662&amp;include=eJyNjEEKgDAMBD8k9UkhTQMGSiJNRfp7ayuePHjK7jAblQIRnVdnAq8tsy_a2cnRpTKoVSH29YOF5w5__LiDkOlEqJhbN-b4bQGTRYaMh9L2Q9yLpQuf0kIl"></script>
<script src="../../../assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js" crossorigin="anonymous" async integrity="sha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf"></script>

  </body>
</html>
